Document:

NANOPHASE TECHNOLOGIES CORPORATION – 8-K

EXHIBIT 10.2

  

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

AMENDED AND RESTATED

 

JOINT DEVELOPMENT & SUPPLY AGREEMENT

 

This Amended and Restated
Joint Development & Supply Agreement (“Agreement”) is made this 15th day of
May, 2018 (“Effective Date”) between COLORESCIENCE Inc., a company existing and organized under the
laws of Delaware, (“COLORESCIENCE”) with its principal place of business at 2141 Palomar Airport
Road, Suite 200, Carlsbad, CA 92011, and SOLÉSENCE, LLC, a company existing and organized under the laws of
Delaware, with its principal place of business at 1319 Marquette Drive, Romeoville, Illinois
60446 (“SOLÉSENCE”), (collectively, the “Parties”).

 

WHEREAS, both COLORESCIENCE and
SOLÉSENCE desire to develop sunscreen actives and related formulations to:

 

		1.	Provide a near term solution to help bridge the supply gap that is being created by the [*], without
losing water resistance or SPF performance as compared to the performance of the current powder sunscreen products.

 

		2.	Establish a platform technology that will serve as the basis for innovations in sunscreen based
products. Enable novel ‘one of a kind’ positioning for COLORESCIENCE versus competitive products.

 

		3.	Targeted key enhancements for powder sunscreens are the improvement in adherence and hydrophobicity,
while boosting antioxidant efficacy as measured by Antioxidant Power Method and achieving best in class free radical protection
as measured by Radical Status Factor Method. Both methods are performed by Gematria Laboratories.

 

		4.	Targeted key enhancement for emulsions and liquid products are enhancing physical sunscreen performance
while boosting antioxidant efficacy as measured by Antioxidant Power Method, achieving best in class free radical protection as
measured by Radical Status Factor Method and protecting from pollution and other environmental and light sources. Both Antioxidant
Power Method and Radical Status Factor Method are performed by Gematria Laboratories.

 

WHEREAS, COLORESCIENCE wishes to
exclusively purchase from SOLÉSENCE and SOLÉSENCE wishes to produce and sell exclusively to COLORESCIENCE the Innovation
Solution Actives, Finished Product A, Finished Product B and Next Gen Product(s) (as each is defined herein);

 

WHEREAS, the Parties entered into
that certain Joint Development & Supply Agreement dated December 12, 2016 (the “Original Agreement”)
to provide for the development and supply of the Exclusive Products (as defined herein) and related matters as provided therein;
and

  

     

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

WHEREAS, the
Parties desire to amend and restate the Original Agreement in its entirety as set forth below;

 

NOW THEREFORE, for adequate consideration,
receipt of which is hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:

 

		1.	Definitions. For the purpose of clarity, the following terms
are used in this Agreement:

 

		1.1.	“Affiliate(s)” means any Person (defined below) which directly or indirectly
controls, is controlled by, or under common control with a Party. For purposes of the foregoing definition, the term “control”
(including with correlative meaning, the terms “controlling”, “controlled by”,
and “under common control with”) as used with respect to any Person, shall mean the possession, directly
or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership
of voting securities, by contract, or otherwise. “Person” means an individual, corporation, partnership,
limited liability company, firm, association, joint venture, estate, trust, governmental or administrative body or agency, or any
other entity.

 

		1.2.	“Bridge Solution” means the TiO2 Sunscreen Active developed
by SOLÉSENCE to supply as a replacement for the [*] materials currently used by COLORESCIENCE in their formulas.

 

		1.3.	“COLORESCIENCE Technology” means all COLORESCIENCE and COLORESCIENCE
Affiliate Confidential Information, intellectual property and developments (including all trade secrets, know-how, inventions,
designs, concepts, formulations, works of authorship, technical information, manuals, instructions or specifications) owned or
developed by COLORESCIENCE or its Affiliates or provided by COLORESCIENCE or its Affiliates to SOLÉSENCE in connection with
the activities performed under or contemplated by this Agreement and any Improvements by COLORESCIENCE to any of the foregoing,
including, without limitation, patents, patent applications, trade secrets, know-how, inventions, designs, concepts, Improvements,
technical information, works of authorship, copyrightable materials, including manuals and instructions, Product Specifications,
trademarks, trade dress or trade names, and the Intellectual Property Rights related to any of the foregoing. COLORESCIENCE Technology
includes, without limitation, COLORESCIENCE’s existing products, formulations and information, and Improvements or inventions
arising from the development of the SPF 50 Innovation Powder Formula that are not Innovation Solution Actives.

 

		1.4.	“Exclusive Field” means, on an Exclusive Product-by-Exclusive Product
basis:

 

		(i)	With respect to the Innovation Solution Actives: the use in the SPF 50 Powder Innovation Formula
for inclusion in Environmental Protection Products which utilize the Exclusive Application and are marketed and sold through any
and all channels.

 

		(ii)	With respect to Finished Product A, Finished Product B and any Next Gen Products: the Professional
Channel.

 

		1.5.	“Environmental Protection Product(s)” means sunscreens and skincare products,
preparations, and formulations offering protection from one or more environmental effects, including, without limitation, ultraviolet,
infrared and high-energy visible light, pollution, smog, particulates, dust, soot, smoke, acid, chemicals, aerosols, and/or other
hazards and contaminants.

 

		1.6.	“Exclusive Application” means pigmented powder products for use on human
skin using a flow-through brush as the applicator.

 

		1.7.	“Exclusive Product(s)” means the Innovation Solution Actives, Finished
Product A, Finished Product B, and the Next Gen Product.

 

		1.8.	“Finished Product(s)” means Finished Product A and Finished Product B.

 

    2

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		1.9.	“Finished Product A” means the emulsion/gel Environmental Protection
Product developed by COLORESCIENCE and SOLÉSENCE intended for application to a user’s face, provisionally named the
Sunforgettable Total Protection Face Shield.

 

		1.10.	“Finished Product B” means the Environmental Protection Product intended
for application to a user’s body, provisionally named the Sunforgettable Total Protection Body Shield.

 

		1.11.	“Finished Products” means Finished Product A and Finished Product B.

 

		1.12.	“Improvements” means all inventions, discoveries, technical developments
and know-how, including trade secrets, whether or not patentable, conceived and/or reduced to practice by a party that are an improvement,
enhancement and/or modification of a Party’s intellectual property and/or technology.

 

		1.13.	“Innovation Solution Active(s)” means the TiO2 and ZnO Sunscreen Actives,
the formulations for which have been developed specifically for use with the SPF 50 Powder Innovation Formula and and other product
reformulations as mutually agreed by the Parties and added to Exhibit B to this Agreement from time to time and the criteria
within Development Objective 2.

 

		1.14.	“Innovation SPF 50 Powder Sunscreen” means the sunscreen product produced
by COLORESCIENCE containing the SPF 50 Innovation Powder Formula.

 

		1.15.	“Intellectual Property Rights” means all trade secrets, copyrights, patents
and other patent rights, trademarks, service marks, moral rights, know-how and any and all other intellectual property or proprietary
rights (including, without limitation, applications relating thereto) in any inventions, compounds, formulations, techniques, works,
know-how or discoveries, whether or not patentable or registrable, now known or hereafter recognized in any jurisdiction.

 

		1.16.	“Know How” means all confidential and proprietary information and data
controlled by SOLÉSENCE as of the Effective Date and Improvements thereto developed or reduced to practice during the Term
of this Agreement that relate to the inventions and technology described in the Patent Rights, including any and all tangible and
intangible information and materials, including research and development data, regulatory submissions and correspondence, manufacturing
information and processes, formulations, assays, cell lines, sequences, composition of matter, constructs, discoveries, improvements,
modifications, processes, methods, protocols, formulas, utility, data (including physical, chemical, biological, toxicological,
pharmacological, preclinical, clinical, and veterinary data), results, inventions, know-how and trade secrets, patentable or otherwise,
and all other scientific, marketing, financial and commercial information or data, but excluding any of the foregoing to the extent
described or claimed in any Patent Rights.

 

		1.17.	“Next Gen Product(s)” means any future products developed under this
Agreement as mutually agreed by the Parties and added to Exhibit B to this Agreement from time to time.

 

		1.18.	“Non-Exclusive Product(s)” means the Bridge Solution.

 

		1.19.	“Patent Rights” means: (a) the patents and patent applications listed
on Exhibit C to this Agreement and any other patents and/or patent applications controlled by SOLÉSENCE and or its
Affiliates at any time during the Term which claim or otherwise cover the Innovation Solution Actives or the use, manufacture or
formulation thereof; (b) any patents and patent applications arising from Improvements covered by Section 14.1.3 of this Agreement;
(c) all regular, divisional, continuation, substitution, continuation-in-part, and continued prosecution applications that claim
priority to those patents or patent applications described in subsections (a) and (b); (c) all patents that have issued or in the
future issue from any of the foregoing patent applications in subsections (a) and (b), including utility, model and design patents,
certificates of invention and applications for certificates of invention; (d) any reissues, renewals, extensions (including patent
term extensions and supplemental certificates and the like), adjustments, re-examinations, revalidations, registrations and pediatric
exclusivity periods of any of the foregoing; and (e) any foreign equivalents of any of the foregoing.

 

    3

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		1.20.	“Product(s)” means the Exclusive Products, the Non-Exclusive Products,
the SPF 50 Powder Innovation Formula, and any Environmental Protection Products containing the Innovation Solution Active.

 

		1.21.	“Product Specifications” means those specifications, requirements, and
acceptance criteria described in Exhibit B to this Agreement.

 

		1.22.	“Professional Channel” means marketing and sales directly or indirectly
to end users through medical offices and facilities, and spas and other facilities with which a medical director is associated,
and other sales by or on behalf of medical professionals, including through the internet or directly from a medical professional.

 

		1.23.	“Solesence Technology” means (i) the Patent Rights; (ii) the Know-How;
(iii) all SOLÉSENCE and SOLÉSENCE Affiliate Confidential Information, intellectual property and developments (including
all trade secrets, know-how, inventions, designs, concepts, formulations, works of authorship, technical information, manuals,
instructions or specifications) owned or developed by SOLÉSENCE or its Affiliates or provided by SOLÉSENCE or its
Affiliates to COLORESCIENCE in connection with the activities performed under or contemplated by this Agreement and any Improvements
by SOLÉSENCE to any of the foregoing, including, without limitation, patents, patent applications, trade secrets, know-how,
inventions, designs, concepts, Improvements, technical information, works of authorship, copyrightable materials, including manuals
and instructions, Product Specifications, trademarks, trade dress or trade names; (iv) SOLÉSENCE’s and its Affiliates’
interest in Joint IP; and (iv) all Intellectual Property Rights related to any of the foregoing.

 

		1.24.	“Solesence Trademarks” means those trademarks and tradenames of SOLÉSENCE
listed in Exhibit E to this Agreement.

 

		1.25.	“SPF 50 Powder Innovation Formula” means the Powder Sunscreen formula
developed by COLORESCIENCE as a replacement for COLORESCIENCE’s current SPF 50 Powder, designed to utilize the Innovation
Solution Actives and meet the requirements of Development Objective 3.

 

		1.26.	“Sunscreen Active(s)” means formulations or preparations of titanium
dioxide (TiO2) and/or zinc oxide (ZnO) for use in Products.

 

		1.27.	“Supply Agreement” means the contractual agreement entered into by the
Parties providing the terms and conditions for supply of the Bridge Solution and the Exclusive Products by SOLÉSENCE to
COLORESCIENCE.

 

		1.28.	“Territory” means worldwide.

 

		2.	Roles and Responsibilities

 

In order to achieve the timely development
of the Bridge Solution, the Innovation Solution Actives, the Finished Products and the Next Gen Product, COLORESCIENCE and SOLÉSENCE
agree to the following Roles and Responsibilities:

 

    4

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		2.1.	Roles and Responsibilities of COLORESCIENCE

 

		2.1.1.	Provide the materials and composition of all existing formulations to use the Bridge Solution;

 

		2.1.2.	Establish final product launch criteria for the Bridge Solution;

 

		2.1.3.	Perform SPF and related clinical testing for confirmation of the performance;

 

		2.1.4.	Perform stability testing in conjunction with SOLÉSENCE of formulas using the Bridge Solution;
and

 

		2.1.5.	Enable production of pilot and production quantities of powder materials as required within the
development plans in Exhibit A to this Agreement.

 

		2.2.	Roles and Responsibilities of SOLÉSENCE

 

		2.2.1.	Meet the timeline provided for the development of the Bridge Solution and the Innovation Solution
Actives as provided in Exhibit A;

 

		2.2.2.	Perform the stability testing for Bridge Solution and the Innovation Solution Actives to allow
for a minimum three-year shelf life;

 

		2.2.3.	Perform the stability testing in conjunction with COLORESCIENCE for the COLORESCIENCE’s products
using the Bridge solution;

 

		2.2.4.	Perform the stability testing in conjunction with COLORESCIENCE for Finished Product A;

 

		2.2.5.	Perform the stability testing in conjunction with COLORESCIENCE for Finished Product B; and

 

		2.2.6.	Perform efficacy testing related to Antioxidant Power and Radical Protection Factor to establish
these claims with products produced using the Innovation Solution Actives.

 

		2.3.	Production Obligations

 

		2.3.1.	SOLÉSENCE shall produce pilot and production quantities of the Bridge Solution, the Innovation
Solution Actives, Finished Product A, and Finished Product B as required within the development plans in Exhibit A.

 

		2.3.2.	Without limiting the generality of the foregoing, SOLÉSENCE shall develop and deliver to
COLORESCIENCE Finished Product A for launch by COLORESCIENCE by [*] and COLORESCIENCE agrees to accept first delivery of Finished
Product A. SOLÉSENCE shall develop and deliver to COLORESCIENCE Finished Product B by [*]. Each Finished Product will be
manufactured and supplied to COLORESCIENCE by SOLÉSENCE as a finished article in accordance with all product specifications
and applicable law.

 

		2.4.	Branding; Promotional Materials. COLORESCIENCE will promote and sell the Products under trademarks
selected by COLORESCIENCE, which trademarks shall be owned and shall remain the property of COLORESCIENCE. COLORESCIENCE shall
have the right but not the obligation to use SOLÉSENCE Trademarks on Products utilizing the Innovation Solution Actives
and/or related marketing materials when reasonable and practicable at the sole discretion of COLORESCIENCE. Except as set forth
in this Section 2.4, nothing herein shall be deemed to give SOLÉSENCE, its Affiliates, and/or their respective suppliers,
either during the Term or thereafter, any right to trademarks or copyrights of COLORESCIENCE or to their use unless written consent
is obtained from COLORESCIENCE. COLORESCIENCE will create and develop all promotional materials with respect to the Products.

 

    5

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		2.5.	Patent Marking. COLORESCIENCE agrees, to the extent commercially reasonable and consistent with
prevailing business and legal practices, to mark and use reasonable efforts to have each of its Affiliates and sublicensees mark
all Products covered by the Patent Rights under this Agreement in accordance with the applicable statute or regulations relating
to patent marking in the country or countries of manufacture and sale thereof.

 

		2.6.	Development. The Parties shall work together in good faith, using commercially reasonable efforts,
on the development of two additional products during the first thirty (30) months of the Term. COLORESCIENCE and SOLÉSENCE
will engage in at least one yearly pipeline development discussion to review additional products that may be suitable for SOLÉSENCE
to provide COLORESCIENCE. It is both Parties intention to continue to explore future product innovation opportunities together
in the liquid product category.

 

		3.	Exclusivity

 

		3.1.	SOLÉSENCE License Grant.

 

		3.1.1.	Exclusive License. SOLÉSENCE hereby grants to COLORESCIENCE an exclusive (even as against
SOLÉSENCE and its Affiliates except with respect to its development and manufacturing obligations hereunder and the exceptions
noted on Exhibit F to this Agreement) license under the Solesence Technology to sell, offer to sell, import, market, promote,
distribute and use Exclusive Products in the Territory in the applicable Exclusive Field.

 

		3.1.2.	Non-Exclusive License. SOLÉSENCE hereby grants to COLORESCIENCE a non-exclusive license
under the Solesence Technology to sell, offer to sell, import, market, promote, distribute and use Non-Exclusive Products in the
Territory in all fields.

 

		3.1.3.	Trademarks. SOLÉSENCE hereby grants to COLORESCIENCE a non-exclusive license to use, for
the purposes of promoting and selling Products containing the Innovation Solution Actives, the Solesence Trademarks. Prior to,
and after, the use of Solesence Trademarks, COLORESCIENCE shall inform SOLÉSENCE of the planned method of use of the trademark.

 

		3.2.	Sublicensing. COLORESCIENCE shall have the right to grant sublicenses for the licenses and rights
granted under this Agreement and to otherwise utilize one or more Affiliates and/or third parties to distribute, market and/or
promote the Products to the same extent that COLORESCIENCE holds such rights, without the consent of or notice to SOLÉSENCE.
COLORESCIENCE shall be responsible for ensuring that any of its sublicensees’ exercise of such rights complies with the terms
of this Agreement.

 

		3.3.	Sufficiency of Licensed Rights. SOLÉSENCE hereby represents and warrants that neither it
nor its Affiliates owns or controls any Intellectual Property Rights, other than the licenses and rights granted to COLORESCIENCE
under this Agreement, covering, claiming or directed to any Products or the formulation, development, manufacture, use, sale, offer
for sale, import or other commercial exploitation thereof in accordance with the terms of this Agreement by COLORESCIENCE and/or
its Affiliates and/or each of their respective successors, assigns (including successors and/or assigns to any Products or Product
lines of COLORESCIENCE and/or its Affiliates), suppliers, distributors, resellers, customers, agents, licensees (or sublicensees),
or agents.

 

    6

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		3.4.	For so long as COLORESCIENCE meets the minimum purchase and payment requirements as provided in
Exhibit A and further described in Section 3.7 below and without limiting the exclusive rights granted under Section 3.1, neither
SOLÉSENCE nor any of its Affiliates shall directly or indirectly develop, manufacture, market, distribute or sell, or license
or grant any third party any rights (including any covenants not to sue) to develop, manufacture, market, distribute or sell: (i)
any Environmental Protection Products that are covered or claimed by, are developed or manufactured using, embody, incorporate,
utilize, rely on or arise or benefit from any of the Solesence Technology (including, without limitation, any and all Exclusive
Products), and which are intended for or are otherwise distributed, marketed and/or sold through the Professional Channel (other
than on behalf of COLORESCIENCE pursuant to this Agreement); or (ii) any Environmental Protection Products in any channel that
(a) utilize the Exclusive Application or (b) contain [*] or [*] (all of the above, collectively, “Competing Products”);
except for the limited exceptions set forth in Exhibit F (the obligations of SOLÉSENCE and its Affiliates under this
Section 3.4, the “Exclusivity Commitment”).

 

		3.5.	Exclusivity & Development Fee: In exchange for the grant of exclusive rights as contemplated
in this Agreement, and to encourage SOLÉSENCE to perform under the terms of this Agreement and help defray the cost SOLÉSENCE
will incur with meeting its responsibilities under this agreement, the Parties acknowledge that COLORESCIENCE has paid to SOLÉSENCE
a development fee in the amount of $[*]. In addition, the Parties acknowledge that COLORESCIENCE has paid to SOLÉSENCE
an additional $[*] in development fees in the first quarter of 2018 to support further analytical and development needs in order
to support the launch of the Innovation SPF 50 Powder Sunscreen.

 

		3.6.	Success Fee: COLORESCIENCE agrees to pay SOLÉSENCE $[*] within thirty (30) days after COLORESCIENCES’
first commercial sale of the Innovation SPF 50 Powder Sunscreen, which is anticipated to occur in Q1 or Q2 of 2018.

 

3.7.        
Minimum Order Quantities of Products

 

		3.7.1.	Subject to SOLÉSENCE’s compliance with this Agreement, including timely fulfilling
its supply obligations hereunder, COLORESCIENCE agrees to collectively order the minimum order quantities appearing on Exhibit
A (the “Minimum Order Quantity(ies)”) for the Term of this Agreement, provided that, with respect to
Finished Products, SOLÉSENCE shall have developed such Finished Products according to the applicable Product Specifications
developed by COLORESCIENCE and with aesthetics and performance characteristics on par with other production sites contemporaneously
being used by COLORESCIENCE. The standard for assessing such quality standards will be solely determined by COLORESCIENCE using
a commercially reasonable standard. In the event that COLORESCIENCE and SOLÉSENCE do not reach agreement on the aesthetics
or performance of the Finished Products developed by SOLÉSENCE, the Parties will employ a consumer panel to make final determination
of the product attributes in light of commercially reasonable standards.

 

 

    7

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		3.7.2.	In the event that COLORESCIENCE does NOT meet the Minimum Order Quantity for a Product as provided
in Exhibit A and such failure was not due to a Force Majeure Event or a breach or failure of SOLÉSENCE to comply with its
obligations under this Agreement, COLORESCIENCE may elect, subject to Section 3.7.3 below, to maintain exclusivity by paying SOLÉSENCE
an R&D fee (the “R&D Fee”) within sixty days after the end of each calendar year, as follows:

 

	Product	R&D Fee
	
        Bridge Solution

        

        Innovation Solution Active

         
	[*]% of the difference of (i) the value of the units actually ordered at the Price per Ounce in Exhibit A, minus (ii) the value of the Minimum Order Quantity of the Product at the Price per Ounce in Exhibit A
	Finished Products A and B, and Next Gen Product(s),  collectively	The greater of (i) $[*] or (ii) [*]% of the average purchase price of the units of Finished Products purchased, multiplied by the difference between (a) the Minimum Order Quantity of Finished Products and (b) the number of units of Finished Products actually purchased by COLORESCIENCE

 

In the event
COLORESCIENCE does not meet the Minimum Order Quantities provided in Exhibit A with respect to a Product and does not timely pay
the R&D Fee, and if COLORESCIENCE’s inability to meet the Minimum Order Quantity did not result from a Force Majeure
Event or SOLÉSENCE’s breach or failure to comply with its obligations under this Agreement, including to timely supply
such Product in accordance with the Product Specifications, then as SOLESENSE’s sole and exclusive remedy and COLORESCIENCES’s
sole and exclusive liability, the license granted in Section 3.1 and the Exclusivity Commitment provided in Section 3.4 with respect
to such Product may be reduced from exclusive to non-exclusive upon written notice thereof by SOLÉSENCE. Notwithstanding
the foregoing, in the event that COLORESCIENCE does not intend to meet the Minimum Order Quantities or pay the pro-rated R&D
Fee in 2019 or a future year as a result of such shortfall, COLORESCIENCE shall notify SOLÉSENCE of such intent by September
30, of that year. If COLORESCIENCE fails to timely provide such notification, COLORESCIENCE shall be obligated to either meet the
Minimum Order Quantity or pay the shortfall R&D Fee for that calendar year.

 

		3.7.3.	Should SOLÉSENCE sell to COLORESCIENCE any units
of Finished Products A, B, or Next Gen Product(s) intended for use in a marketing campaign or as full-sized testers at a sales
price lower than the pricing provided in Exhibit A (such lower price, the “Reduced Sales Price”) then
the quantities of such Products sold at the Reduced Sales Price shall contribute towards the applicable Minimum Order Quantities
at a prorated amount equal to the Reduced Sales Price as a percentage of the price provided in Exhibit A multiplied by the total
units sold at the Reduced Sales Price. For clarity any non-full-sized samples (including luxury samples) created for Colorescience
shall not be included towards the applicable Minimum Order Quantity.

 

		3.7.4.	Notwithstanding anything to the contrary in this Section 3.7, COLORESCIENCE shall submit purchase
orders equal to the annual minimum order quantity for Innovation Actives and Finished Products as listed in Exhibit A or pay the
equivalent pro-rated R&D Fee, in the first sixty 60 days after the completion of the calendar year of the agreement.

 

		3.7.5.	If in a given year COLORESCIENCE exceeds the previous year’s Minimum Order Quantity for a
Product, then the Minimum Order Quantity for such Product shall be reduced by one half of the previous year’s excess (Offset),
while under no circumstance shall COLORESCIENCE pay less than [*]% of the Minimum Order Quantity even after accounting for the
Offset.

 

    8

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		4.	Term and Termination

 

		4.1.	This Agreement shall enter into force on the Effective Date and shall remain in force for a twelve
(12) year, non-cancelable term, renewable upon written notice for up to two (2) additional five (5) year terms upon mutual agreement
of both parties (altogether, the “Term”). Notice of intent to renew this agreement shall be provided
not less than sixty (60) days prior to end of the current Term.

 

		4.2.	Termination by COLORESCIENCE.

 

		4.2.1.	In the event that COLORESCIENCE discontinues the Innovation SPF 50 Powder Sunscreen for any reason,
COLORESCIENCE shall have the right to terminate this Agreement upon 120 days’ notice to SOLÉSENCE. All fees earned
to date shall be owed to SOLÉSENCE.

 

		4.2.2.	If SOLÉSENCE (a) fails to timely supply, according
to the terms of supply as provided by Section 8, any Products ordered by COLORESCIENCE for a period of greater than sixty (60)
days and such failure was not due to a Force Majeure Event or a breach or failure of COLORESCIENCE to comply with its obligations
under this Agreement, (b) fails to timely supply, according to the terms of supply as provided by Section 8, any Products ordered
by COLORESCIENCE for a period of greater than six (6) months and such failure was due to a Force Majeure Event, or (c) otherwise
materially breaches any of the provisions of this Agreement and such breach is not cured within seventy-five (75) days after COLORESCIENCE
gives written notice of such breach to SOLÉSENCE, then COLORESCIENCE shall have the right to: (i) use a third-party manufacturer
to supply such Products as provided in Section 5.1.2 until such time that SOLÉSENCE cures the breach; or (ii) terminate
this Agreement.

 

		4.2.3.	COLORESCIENCE shall have the right to terminate this Agreement immediately with respect to any
Product that any governmental or regulatory agency (including, by way of example, the U.S. Food and Drug Administration) determines
to be unsafe or otherwise prohibits COLORESCIENCE from marketing or selling.

 

		4.2.4.	If SOLÉSENCE breaches the warranty contained in Section 10.2.6(e), or if any of the Solesence
Technology is adjudicated to be void, invalid, or unenforceable, then without limiting any other remedies provided by this Agreement
or otherwise available to COLORESCIENCE under law or in equity, COLORESCIENCE may immediately terminate this Agreement, in whole
or in part, and may immediately cancel any unfilled accepted orders without liability. If a U.S. District Court or any court worldwide
adjudges that any Product, or any item or part thereof, or the use thereof infringes any United States patent or any patent worldwide,
irrespective of whether further right of appeal lies available to SOLÉSENCE, or if any Product or use thereof is enjoined
at any stage of the proceedings, any unfilled accepted orders will be canceled without liability for COLORESCIENCE

 

		4.3.	Termination by SOLÉSENCE: If COLORESCIENCE: (a) fails to meet payment terms as provided
in Section 8 of this agreement and does not cure within another sixty (60) days; (b) becomes insolvent or declares bankruptcy,
or (c) otherwise materially breaches this Agreement and such breach is not cured within seventy-five (75) days after SOLÉSENCE
gives written notice of such breach to COLORESCIENCE, then SOLÉSENCE shall have the right to terminate this agreement upon
60 days of written notice to COLORESCIENCE.

 

    9

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		4.4.	Effect of Termination. Subject to the exceptions set forth in this paragraph, in the event of termination
of this Agreement for any reason, the licenses and rights granted hereunder by SOLÉSENCE to COLORESCIENCE shall terminate,
and shall revert to SOLÉSENCE, and COLORESCIENCE shall not thereafter make any use whatsoever of the SOLÉSENCE Trademarks
or the Products. Notwithstanding the foregoing, the licenses and rights granted under this Agreement by SOLÉSENCE to COLORESCIENCE
shall remain in full force and effect: (i) upon exercise by COLORESCIENCE of its right to use a third-party to supply Product pursuant
to Section 4.2.2, with no further payment obligations to SOLÉSENCE, and without prejudice to any other remedies COLORESCIENCE
may have against SOLÉSENCE or that SOLÉSENCE may have against COLORESCIENCE for such breach; and (ii) upon termination
of this Agreement for any reason, for the shelf life of any Products manufactured or in process prior to the date of termination
of this Agreement in order to provide COLORESCIENCE and its Affiliates, sublicensees, resellers, distributors, marketing partners,
agents and assigns sufficient time to sell off the existing inventory of the Products or related marketing materials (including,
at COLORESCIENCE’s option, orders in process and/or in SOLÉSENCE’s possession but not yet completed or shipped),
provided that COLORESCIENCE shall continue to pay any amounts payable thereon as provided in this Agreement. COLORESCIENCE shall
remain obligated to meet any payment obligations to SOLÉSENCE or its permitted assigns established prior to the termination
of this Agreement.

 

		4.5.	The rights and obligations of each of the Parties hereto under any provision of this Agreement,
which, by its terms, is intended to survive beyond the term of this Agreement, shall continue notwithstanding the expiration or
termination of this Agreement for any reason.

 

		5.	Commitment to Supply

 

		5.1.	COLORESCIENCE shall provide SOLÉSENCE a forecast of COLORESCIENCE’s requirements for
Products on a quarterly basis as provided in Section 7.2 below.

 

		5.1.1.	It is understood that the Products are intended to be a critical component of COLORESCIENCE’s
most important franchise products. SOLÉSENCE shall enable supply, establish and maintain an inventory at its facility equivalent
to at least three months’ supply based upon COLORESCIENCE’s most recent forecasts, provided that with respect to the
Innovation Solution Actives, SOLÉSENCE shall maintain an inventory at its facility equivalent to at least six months’
supply based upon COLORESCIENCE’s most recent forecasts. SOLÉSENCE will within 120 days of the commercialization of
each Product, qualify a third party manufacturer (the “Qualified Manufacturer”) acceptable to COLORESCIENCE
to produce such Product consistent with the Product Specifications. Should SOLÉSENCE be unable for a period of 60 days to
supply any Products for any reason whatsoever, SOLÉSENCE shall compel the Qualified Manufacturer to produce such Products
on SOLÉSENCE’s behalf. Upon resumption of production capability, SOLÉSENCE shall resume production and supply
of such Products to COLORESCIENCE.

 

		5.1.2.	Should SOLÉSENCE due to insolvency, breach,
Force Majeure Event or any other reason be unable or otherwise fail to supply any Products for a period of greater than 75 days
(provided that in the event of a Force Majeure Event, such period shall be greater than six (6) months), and such failure was
not due to a breach or failure of COLORESCIENCE to comply with its obligations under this Agreement, COLORESCIENCE shall have
the right to have the Qualified Manufacturer or, if such Qualified Manufacturer is unable to meet the supply obligations under
this Agreement, an alternative manufacturer chosen by COLORESCIENCE, produce and supply such Products directly for COLORESCIENCE,
until such time as SOLÉSENCE can resume supply. Any agreement between SOLÉSENCE and the Qualified Manufacturer shall
provide that COLORESCIENCE shall have the right to purchase Products at prices no greater than the prices provided in this Agreement.
To the extent such price is less than that provided under this Agreement, COLORESCIENCE agrees to provide such differential to
the then owner of U.S. Patent 9,139,737 provided that (i) such Patent Rights has validly issued claim covering such Product at
the time of manufacture and (ii) in no event shall such royalty payment constitute more than [*]% of the total purchase price
of such Product from the Qualified Manufacturer. COLORESCIENCE and the Qualified Manufacturer shall only have the rights to use
SOLÉSENCE technology for the manufacture of Products. SOLÉSENCE maintains all rights to take legal action should
Qualified Manufacturer alone or by the direction of COLORESCIENCE or COLORESCIENCE use SOLÉSENCE technology for other than
the manufacture of Products.

 

    10

     

    

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted
information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together
with such request for confidential treatment.

 

		6.	Quality of Product

 

		6.1.	SOLÉSENCE shall deliver to COLORESCIENCE the Bridge Solution and Exclusive Products in compliance
with the Product Specifications set forth in Exhibit B to this Agreement. Exhibit B, which is a part
hereof, may be modified from time to time upon the mutual written agreement of the Parties, including to incorporate the development
of new products, and shall be the final and exclusive description of the quality and all material properties of the Bridge Solution
and the Exclusive Products.

 

		6.2.	SOLÉSENCE, for itself and its Affiliates and suppliers, shall provide COLORESCIENCE with
full access to all data generated by SOLÉSENCE, its Affiliates and/or its suppliers on the Products which is necessary to
support COLORESCIENCE’s regulatory filings or other governmental or regulatory approvals with respect to the Products or
which is necessary to respond to inquiries made by any governmental or regulatory authority with respect to the Products. In addition,
COLORESCIENCE, at its expense, shall have the right to conduct studies with the Products for regulatory and commercial purposes.
COLORESCIENCE will own all data and results from such studies.

 

		6.3.	The Parties will each maintain traceability records necessary to permit a recall, field correction
or other notification to the field of any Product. Each Party will give telephonic notice (to be confirmed in writing) to the other
within twenty-four (24) hours of the receipt of any information which indicates a recall, field correction or other notification
to the field may be necessary. Except as otherwise required by applicable law, the decision to conduct and the right to control
a recall, field correction or any other notification to the field will be solely that of COLORESCIENCE. Each party will cooperate
fully with the other in connection with any such efforts. To the extent any recall, field correction or other notification to the
field is due to a breach by SOLÉSENCE of its obligations under this Agreement, or the negligence or willful misconduct of
SOLÉSENCE, SOLÉSENCE will replace the recalled or field corrected Products with conforming Products and will reimburse
COLORESCIENCE for all of COLORESCIENCE’s reasonable and documented costs and expenses, both direct and indirect, actually
incurred by COLORESCIENCE in connection with the recall, field correction or other notification to the field, including, but not
limited to, the costs of retrieving any Product already delivered to customers and costs and expenses COLORESCIENCE is required
to pay for the replacement of the Product and the notification, shipping and handling charges. In all other cases, COLORESCIENCE
will reimburse SOLÉSENCE for all of SOLÉSENCE’s reasonable and documented costs and expenses, both direct and
indirect, actually incurred by SOLÉSENCE in connection with the recall, field correction or other notification to the field
with respect to any Products.

 

		7.	Quantity of Product

 

		7.1.	SOLÉSENCE shall deliver the quantity of each Product specified in each order by COLORESCIENCE
and COLORESCIENCE shall pay for such quantity of Product meeting the applicable Product Specifications and accepted by COLORESCIENCE.

 

    11

     

    

 

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment. 

 

		7.2.	COLORESCIENCE
                                         shall provide SOLÉSENCE with rolling forecasts of COLORESCIENCE’s expected
                                         requirements for the Product (the “Forecasts”) as follows:

 

		(a)	Each
                                         Forecast shall provide an estimate of the quantity of each Product required during the
                                         next three (3) months.

 

		(b)	COLORESCIENCE
                                         shall notify SOLÉSENCE of any changes to these Forecasts as soon as possible to
                                         allow SOLÉSENCE to make any necessary changes to production schedules. COLORESCIENCE
                                         shall not be responsible for paying for unneeded Products produced or ordered by SOLÉSENCE
                                         in accordance with any Forecast.

 

		8.	Order
                                         Processing and Deliveries

 

		8.1.	COLORESCIENCE
                                         shall provide orders to SOLÉSENCE a minimum of 12 weeks in advance of the requested
                                         delivery date for Products and SOLÉSENCE shall accept each order placed by COLORESCIENCE
                                         within three (3) working days from receipt of such order. From time to time, SOLÉSENCE
                                         may notify COLORESCIENCE that due to scarcity of raw materials used to manufacture Products
                                         that the lead time for purchases has been extended. Notwithstanding anything in 8.1,
                                         SOLÉSENCE shall use every reasonable effort to meet COLORESCIENCE requested delivery
                                         dates that comply with the 12 week lead time. Acceptance of an order by SOLÉSENCE
                                         constitutes a complete and binding contract governed by the terms and conditions of this
                                         Agreement. Minimum quantities in regards to purchase orders placed by COLORESCIENCE with
                                         SOLÉSENCE for Finished Products A, B, and Next Gen Product(s) shall be for at
                                         least 15,000 units for the retail items or its equivalent in terms of total bulk quantities
                                         for orders placed that include samples or testers, unless otherwise agreed by the Parties.

 

		8.2.	SOLÉSENCE
                                         shall use best efforts to deliver the ordered Products to COLORESCIENCE at the location
                                         specified by COLORESCIENCE within 56 days of receipt of the applicable order, and in
                                         any event no later than 84 days of receipt of such order. The terms for delivery are
                                         Exworks SOLÉSENCE manufacturing location. All delivery conditions apply in accordance
                                         with the most recent Incoterms.

 

		8.3.	Title
                                         to and risk of loss of Products covered by an accepted order shall transfer to COLORESCIENCE
                                         upon Delivery (see note above).

 

		8.4.	SOLÉSENCE
                                         may invoice COLORESCIENCE for each shipment of Products upon shipment. COLORESCIENCE
                                         shall pay each invoice for accepted Products within [*] days of receipt of such
                                         invoice. Solesence shall be due 0.5% interest per week for the first month and 1% thereafter
                                         on any outstanding, undisputed invoices after this [*] day period. Notwithstanding
                                         the foregoing, with respect to Invoice # [____________], COLORESCIENCE shall pay $[*]
                                         due pursuant to that invoice by June 15, 2018 and shall pay the remainder of that
                                         invoice within [*] days after April 15, 2018. SOLESENCE agrees to offer a [*]% discount
                                         and encourages COLORESCIENCE to attempt to pay invoices within [*] days.

 

		9.	Product
                                         Returns and Non-Conforming Products

 

		9.1.	Any
                                         Product that does not meet the applicable Product Specifications, is delivered more than
                                         fifteen (15) days after the delivery date specified in an order placed and accepted in
                                         accordance with the requirements of this Article 8, or is otherwise not accepted by COLORESCIENCE
                                         (a “Non-conforming Product”) may be returned to SOLÉSENCE
                                         by COLORESCIENCE as set forth in this Article 9. An entire lot of Product may be returned
                                         to SOLÉSENCE by COLORESCIENCE as set forth in this Article 9 if a statistically
                                         significant sampling of that lot contains Non-conforming Product. Any acceptance of Non-conforming
                                         Product shall not be deemed a waiver of the requirement that SOLÉSENCE conform
                                         to the Product Specifications as to future Product.

 

    12 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		9.2.	SOLÉSENCE
                                         shall maintain a quality assurance program and adhere to the quality inspection and testing
                                         procedures described in Exhibit D. SOLÉSENCE shall subject all Product
                                         to such quality inspection testing procedures prior to delivery. SOLÉSENCE shall
                                         provide COLORESCIENCE with access to its quality inspection testing results upon request.

 

		9.3.	All
                                         Products shall be subject to inspection and acceptance by COLORESCIENCE at COLORESCIENCE’s
                                         reasonable discretion. Payment shall not be deemed a waiver of COLORESCIENCE’s
                                         right to inspection or acceptance. No inspection, acceptance or payment shall be binding
                                         on COLORESCIENCE as to latent defects. Without limiting any other rights or remedies
                                         it may have, COLORESCIENCE, at COLORESCIENCE’s option, may (a) store, at SOLÉSENCE
                                         expense and subject to COLORESCIENCE’s disposal, Non-conforming Products, (b) return
                                         Non-conforming Products to SOLÉSENCE, (c) require SOLÉSENCE to repair or
                                         replace any Non-conforming Products, (d) require SOLÉSENCE to issue a credit or
                                         refund to COLORESCIENCE of an amount equal to the amounts paid for any Non-conforming
                                         Products, and/or (e) require SOLÉSENCE to reimburse COLORESCIENCE for the costs
                                         incurred by COLORESCIENCE in procuring conforming goods from an alternate source to the
                                         extent that such costs exceed SOLÉSENCE’s prices (even if not paid) for
                                         the Non-conforming Products. SOLÉSENCE acknowledges and agrees that the provisions
                                         of this Section shall not relieve SOLÉSENCE of any liability under the warranties
                                         set forth in this Agreement or which SOLÉSENCE would otherwise lawfully bear even
                                         after COLORESCIENCE’s inspection and acceptance.

 

		9.4.	All
                                         Non-conforming Product returned to SOLÉSENCE, and all replacement Product shipped
                                         by SOLÉSENCE, will be at SOLÉSENCE’s risk and expense. Risk of loss
                                         of Non-conforming Product returned to SOLÉSENCE will transfer to SOLÉSENCE
                                         upon delivery to SOLÉSENCE’s designated carrier (Meaning: FOB shipping point,
                                         for COLORESCIENCE only).

 

		9.5.	The
                                         Minimum Order Quantities per Exhibit A shall be reduced by an amount equal to the amount
                                         of Non-conforming Product returned to SOLÉSENCE multiplied by a factor of (two)
                                         2.

 

		10.	Representations
                                         and Warranties

 

		10.1.	Each
                                         Party represents and warrants to the other that it has taken all necessary actions on
                                         its part to authorize the execution, delivery and performance of its obligations undertaken
                                         in this Agreement and that this Agreement has been duly executed and delivered by and
                                         on its behalf and constitutes legal, valid and binding obligations enforceable against
                                         it in accordance with its terms.

 

		10.2.	SOLÉSENCE
                                         represents and warrants that:

 

		10.2.1.	it
                                         has the full right, power and authority to grant all of the licenses and rights granted
                                         to COLORESCIENCE under this Agreement;

 

		10.2.2.	there
                                         is no pending or, to the knowledge of SOLÉSENCE, threatened action, suit, proceeding
                                         or claim by any third party that any Solesence Technology infringes, misappropriates
                                         or violates any Intellectual Property Rights or other proprietary rights of any third
                                         party, and SOLÉSENCE has not received any written notice of such claim;

 

		10.2.3.	to
                                         the knowledge of SOLÉSENCE, there is no infringement, misappropriation or violation
                                         by third parties of any Solesence Technology;

 

    13 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment. 

 

		10.2.4.	SOLÉSENCE
                                         owns all right, title and interest in and to the Patent Rights; and

 

		10.2.5.	none
                                         of the Patent Rights have been adjudged invalid or unenforceable, in whole or in part,
                                         and there is no pending or, to the knowledge of the Company, threatened action, suit,
                                         proceeding or claim by any third party challenging the validity or scope of any of the
                                         Patent Rights; and

 

		10.2.6.	each
                                         Product is and will

 

		(a)	conform
                                         to the applicable Product Specifications; be produced in accordance with the quality
                                         inspection and testing program provided in Exhibit D; and be in compliance with all applicable
                                         laws and regulations;

 

		(b)	be
                                         new;

 

		(c)	be
                                         free from defects in design, material and workmanship;

 

		(d)	be
                                         conveyed with good and marketable title, free and clear of all liens or encumbrances;
                                         and

 

		(e)	be
                                         free from violation or infringement of any third party Intellectual Property Rights or
                                         other proprietary rights.

 

		10.3.	All
                                         warranties set forth in Sections 10.1, 10.2.1, 10.2.2, 10.2.3, 10.2.4, and 10.2.5 will
                                         survive any inspection, delivery, acceptance or payment by COLORESCIENCE. The warranties
                                         set forth in Sections 10.2.6(a) and 10.2.6(c) are made and effective at Delivery, are
                                         continuing and will remain in effect for the longer of Supplier’s normal warranty
                                         period or for a period of 180 days following COLORESCIENCE’s acceptance of the
                                         Product. The warranties set forth in Sections 10.2.6(b) and 10.2.6(d) are made and effective
                                         at Delivery. The warranty set forth in Section 10.2.6(e) is made and effective at Delivery,
                                         as is continuing and will remain in effect in perpetuity.

 

		11.	Indemnification

 

		11.1.	SOLÉSENCE
                                         shall defend, indemnify and hold harmless COLORESCIENCE and its Affiliates and their
                                         respective officers, directors, employees, subcontractors, customers, vendors and agents
                                         (the “COLORESCIENCE Indemnitees”) against and from all damages
                                         and claims for damages, suits, causes of action, proceedings, orders, injuries (including
                                         wrongful death) to persons and damages to property of COLORESCIENCE and others, liabilities,
                                         losses, fines, penalties, recoveries, judgments or executions, costs (including attorneys’
                                         fees and costs, and environmental investigation, remediation, clean-up, response and/or
                                         settlement and other similar costs) brought by a third party (“Claims”)
                                         and which arise out of, are caused by, or are incident to: (a) any breach of this Agreement
                                         or any representation, warranty, or covenant contained herein; (b) any negligent or otherwise
                                         wrongful act, omission or conduct of any SOLÉSENCE Indemnitee (as defined below);
                                         (c) any failure of a Product to meet the applicable Product Specifications or be manufactured
                                         hereunder in accordance with applicable law; (d) any claim that the Solesence Technology
                                         and/or Solesence Trademarks or any manufacturing processes utilized by SOLÉSENCE
                                         infringes or misappropriates any Intellectual Property Rights or other proprietary rights
                                         of any third party; or (e) to the extent arising from, connected with or related to the
                                         Solesence Technology or any act, omission or conduct of any SOLÉSENCE Indemnitee:
                                         (i) the death or bodily injury of a person as a result of use of any Products manufactured
                                         by SOLÉSENCE; or (ii) any actual or alleged nonconformities, failures, malfunctions,
                                         defects or deficiencies (whether obvious or hidden and whether or not present in any
                                         Product or sample approved or accepted by COLORESCIENCE) in any Products, or in the design,
                                         construction, fabrication or manufacture of any Products (including the use and/or selection
                                         of materials and/or component parts thereof) or for the use thereof, or for any false
                                         advertising, fraud or misrepresentations or other claims related to the Products or related
                                         marketing or labeling materials; except to the extent caused by the gross negligence,
                                         willful misconduct or breach of this Agreement by any COLORESCIENCE Indemnitee.

 

    14 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		11.2.	COLORESCIENCE
                                         shall defend, indemnify and hold harmless SOLÉSENCE and its Affiliates and their
                                         respective officers, directors, employees, suppliers, subcontractors and agents (the
                                         “SOLÉSENCE Indemnitees”) harmless against and from all
                                         Claims which arise out of, are caused by, or are incident to any breach of this Agreement
                                         or any negligent or otherwise wrongful act, omission or conduct of any COLORESCIENCE
                                         Indemnitee, except to the extent caused by:

 

		(i)	any
                                         failure of a Product to meet the Product Specifications;

 

		(ii)	any
                                         breach of any representation, warranty or covenant made by SOLÉSENCE under this
                                         Agreement; and/or

 

		(iii)	the
                                         gross negligence, willful misconduct or breach of this Agreement by any SOLÉSENCE
                                         Indemnitee.

 

		11.3.	Indemnification
                                         Procedure. Promptly after receipt by a party seeking indemnification under this Article
                                         11 (an “Indemnitee”) of notice of any pending or threatened
                                         Claim against it, such Indemnitee shall give written notice to the Party from whom the
                                         Indemnitee is entitled to seek indemnification pursuant to this Article 11 (the “Indemnifying
                                         Party”) of the commencement thereof; provided that the failure so to notify
                                         the Indemnifying Party shall not relieve it of any liability that it may have to any
                                         Indemnitee hereunder, except to the extent the Indemnifying Party demonstrates that it
                                         is materially prejudiced thereby. The Indemnifying Party shall be entitled to participate
                                         in the defense of such Claim and, to the extent that it elects within ten (10) business
                                         days of its receipt of notice of the Claim from the Indemnitee, to assume control of
                                         the defense and settlement of such Claim (unless the Indemnifying Party is also a party
                                         to such proceeding and the Indemnifying Party has asserted a cross claim against the
                                         Indemnified Party or a court has otherwise determined that such joint representation
                                         would be inappropriate) with counsel reasonably satisfactory to the Indemnitee and, after
                                         notice from the Indemnifying Party to the Indemnitee of its election to assume the defense
                                         of such Claim, the Indemnifying Party shall not, as long as it diligently conducts such
                                         defense, be liable to the Indemnitee for any litigation costs subsequently incurred by
                                         the Indemnitee. No compromise or settlement of any Claim may be effected by the Indemnifying
                                         Party without the Indemnitee’s written consent, which consent shall not be unreasonably
                                         withheld or delayed, provided no consent shall be required if: (a) there is no finding
                                         or admission of any violation of Applicable Laws or any violation of the rights of any
                                         person and no effect on any other claims that may be made against the Indemnitee; (b)
                                         the sole relief provided is monetary damages that are paid in full by the Indemnifying
                                         Party; and (c) the Indemnitee’s rights under this Agreement are not restricted
                                         by such compromise or settlement.

 

		12.	Limitation
                                         of Liability

 

		12.1.	EXCEPT
                                         IN THE EVENT OF A PARTY’S (A) WILLFUL MISCONDUCT OR INTENTIONAL BREACH OR (B) GROSS
                                         NEGLIGENCE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
                                         PUNITIVE, OR INDIRECT DAMAGES (INCLUDING LOST PROFITS OR LOST REVENUES) ARISING FROM
                                         OR RELATING TO THIS AGREEMENT (INCLUDING BREACH OF THIS AGREEMENT) OR THE EXERCISE OF
                                         ITS RIGHTS HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING
                                         THE FOREGOING, NOTHING IN THIS ARTICLE 12 IS INTENDED TO OR SHALL LIMIT OR RESTRICT (1)
                                         THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 11, OR (2) DAMAGES
                                         AVAILABLE FOR A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE
                                         13.

 

    15 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		13.	Confidentiality

 

		13.1.	In
                                         the course of this Agreement the Parties have and will provide proprietary and confidential
                                         information to each other. The Parties are both “Disclosing Party”
                                         and “Receiving Party” as the case may be. The term “Confidential
                                         Information” as used herein shall mean proprietary information including
                                         but not limited to any information, know-how, data, technology, analytical data, mixtures,
                                         recipes, formulas, specifications, manufacturing procedures, customer information, strategies
                                         and business plans as well as product samples that are disclosed or provided to the Receiving
                                         Party or obtained by their evaluation (whether tangible or in electronic form). All Confidential
                                         Information need not be marked as “Confidential” or “Proprietary”
                                         provided that the circumstances of disclosure would lead a reasonable person in the relevant
                                         field to understand that such information was confidential or proprietary.

 

		13.2.	The
                                         Receiving Party shall: (i) hold in strict confidence all Confidential Information disclosed
                                         by the Disclosing Party and protect such Confidential Information with the same standard
                                         of care the Receiving Party affords its own Confidential Information, but no less than
                                         reasonable care; and (ii) not disclose the Confidential Information to any third party
                                         except for its employees, employees of its Affiliates, or its attorneys, accountants,
                                         consultants, agents representatives, contractors, suppliers, potential investors, lenders
                                         or acquirers whose duties justify the need to know such Confidential Information and
                                         who are bound by confidentiality obligations at least as restrictive as those set forth
                                         in this Article 13.

 

		13.3.	The
                                         Receiving Party shall not use the Confidential Information for any purpose other than
                                         the execution of this Agreement, not file for any patent or other intellectual property
                                         registration claiming, disclosing, or referencing such Confidential Information and not
                                         commercially exploit such Confidential Information without the written consent of the
                                         Disclosing Party.

 

		13.4.	The
                                         foregoing restrictions on disclosure and use shall not be applicable to any Confidential
                                         Information which the Receiving Party can prove through tangible evidence that

 

		(a)	are
                                         in the public domain at the time of disclosure;

 

		(b)	are
                                         published or otherwise become part of the public domain through no fault of the Receiving
                                         Party;

 

		(c)	were
                                         in the possession of the Receiving Party at the time of disclosure by the Disclosing
                                         Party as shown by prior written records or became available from a third party who has
                                         the right to legally disclose it and who is not subject to a duty of confidentiality
                                         to the Disclosing Party or any other party;

 

		(d)	were
                                         independently developed by the Receiving Party without using or making any reference
                                         to the Confidential Information;

 

		(e)	are
                                         required to be disclosed pursuant to a law, regulation, rule or ordinance of any governmental
                                         body or court having jurisdiction over either Party provided that the Receiving Party
                                         has given prompt written notice to the Disclosing Party of any such requirement prior
                                         to any disclosure, and provides the Disclosing Party with the opportunity to prevent
                                         or limit such disclosure.

 

		13.5.	Confidential
                                         Information shall not be considered within the above exceptions merely because the Confidential
                                         Information is embraced by more general information within the exceptions. Any combination
                                         of features of Confidential Information shall not be considered within the above exceptions
                                         unless the combination itself and its principles of operation are within the exceptions.

 

    16 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		13.6.	The
                                         Receiving Party shall, upon termination of this Agreement or earlier written request
                                         of the Disclosing Party, promptly return all Confidential Information received from the
                                         Disclosing Party and destroy and delete (and confirm such destruction and deletion in
                                         writing) all copies thereof (whether tangible or in electronic form) containing Confidential
                                         Information.

 

		13.7.	Except
                                         as expressly provided herein, neither this Agreement nor the disclosure of Confidential
                                         Information shall be deemed to constitute the grant of any right or license under any
                                         Confidential Information. Confidential Information shall remain the exclusive property
                                         of the Disclosing Party.

 

		13.8.	The
                                         obligations of confidentiality and nonuse set forth in this Article 13 shall survive
                                         for a period of seven (7) years beyond the termination or expiration of this Agreement;
                                         provided, however, that in the case of Confidential Information comprising a trade secret
                                         of the Disclosing Party, such obligations shall continue for as long as such Confidential
                                         Information qualifies as a trade secret under applicable law.

 

		14.	Intellectual
                                         Property

 

		14.1.	Ownership.

 

		14.1.1.	Background
                                         IP. All Intellectual Property Rights owned or controlled by each Party prior to the Effective
                                         Date or developed independently of the activities performed under or contemplated by
                                         this Agreement and without access or reference to the other Party’s intellectual
                                         property or Confidential Information (“Background IP”), shall
                                         remain the sole property of the Party. No right or license is granted in either Party’s
                                         Background IP except as expressly state herein.

 

		14.1.2.	COLORESCIENCE
                                         Technology. All COLORESCIENCE Technology and all Improvements made by or on behalf of
                                         either Party to the COLORESCIENCE Technology shall be owned exclusively by COLORESCIENCE.
                                         To the extent that SOLÉSENCE acquires any interest in any Improvements to the
                                         COLORESCIENCE Technology, SOLÉSENCE agrees to assign and hereby assigns such interest
                                         to COLORESCIENCE. Any trademarks or copyrights filed by COLORESCIENCE on products related
                                         to independently created or Joint Intellectual Property shall be solely owned by COLORESCIENCE.

 

		14.1.3.	SOLÉSENCE
                                         Technology. All SOLÉSENCE Technology and all Improvements made by or on behalf
                                         of either Party to the SOLÉSENCE Technology shall be owned exclusively by SOLÉSENCE.
                                         To the extent that COLORESCIENCE acquires any interest in any Improvements to the SOLÉSENCE
                                         Technology, including, without limitation, the Bridge Solution and the Innovation Solution
                                         Actives, COLORESCIENCE agrees to assign and hereby assigns such interest to SOLÉSENCE.
                                         Notwithstanding the foregoing, any Improvements made by or on behalf of COLORESCIENCE
                                         to SOLÉSENCE Technology shall not be used or disclosed by SOLÉSENCE for
                                         the benefit of any third party without COLORESCIENCE’s prior written consent. Intellectual
                                         Property Rights associated with manufacturing processes that are generally applicable
                                         to SOLÉSENCE’s industry and do not contain or reference COLORESCIENCE Technology
                                         shall be the exclusive property of SOLÉSENCE, subject to Section 14.1.4 below.
                                         For the avoidance of doubt, SOLÉSENCE shall be free to use, license, and/or sell
                                         such manufacturing processes for any application outside of the Exclusive Application
                                         at SOLÉSENCE’s sole discretion, provided that COLORESCIENCE’s rights
                                         under this Agreement are not impaired by such use, license, or sale.

 

    17 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		14.1.4.	Joint
                                         IP. Inventorship of inventions conceived or reduced to practice in connection with the
                                         activities performed under or contemplated by this Agreement shall be determined by application
                                         of U.S. patent laws pertaining to inventorship. All Intellectual Property Rights developed,
                                         created, generated, conceived, authored or reduced to practice jointly by employees or
                                         contractors of COLORESCIENCE or its Affiliates on one hand, and employees or contractors
                                         of SOLÉSENCE or its Affiliates on the other hand (“Joint IP”),
                                         shall be jointly owned by COLORESCIENCE and SOLÉSENCE. COLORESCIENCE shall have
                                         the exclusive right to market, distribute and sell products covered under Joint IP (“Joint
                                         Products”) and such Joint Products developed will be added to Exhibit
                                         B. Notwithstanding anything to the contrary herein, Finished Product A and Finished
                                         Product B shall be deemed to be Joint Products excluding the Innovation Solution Active(s)
                                         incorporated therein. During the Term, SOLÉSENCE shall have the exclusive right
                                         to manufacture (subject to the provisions of Article 5) Joint Products for all applications,
                                         including for COLORESCIENCE for use within the Exclusive Field, as well as the exclusive,
                                         royalty free right to sell products using the Joint IP for any application outside of
                                         the Exclusive Field (but subject to the limitations of Article 3, including the negative
                                         covenants set forth in Section 3.4).

 

		(a)	Notwithstanding
                                         the foregoing, should COLORESCIENCE’s cumulative purchases of Finished Product
                                         exceed 300,000 units, COLORESCIENCE shall become the sole owner of all Joint IP and all
                                         Intellectual Property Rights and SOLÉSENCE’s interest therein, including
                                         to the formula, related to that Finished Product, and SOLÉSENCE agrees to assign
                                         and upon such occurrence hereby does assign its entire right, title, and interest therein
                                         to COLORESCIENCE.

 

		14.1.5.	Each
                                         Party shall enter into binding agreements obligating all employees, consultants and contractors
                                         performing activities under or contemplated by this Agreement, to assign to such Party
                                         his or her interest in any Intellectual Property Rights conceived, authored or reduced
                                         to practice in the course of such activities.

 

		14.2.	Enforcement.

 

		14.2.1.	Notification
                                         of Infringement. Each Party shall promptly notify the other of any material infringement
                                         or misappropriation of, or proceeding or claim involving, any COLORESCIENCE Technology,
                                         SOLÉSENCE Technology, or Joint IP by a third party or parties, as soon as the
                                         notifying Party learns of such infringement, misappropriation, proceeding, or claim,
                                         and shall provide the other Party with any available evidence of such infringement, misappropriation,
                                         proceeding, or claim.

 

		14.2.2.	COLORESCIENCE
                                         or any of its Affiliates or sublicensees shall have the first right, but not the obligation,
                                         using counsel of its choice, to enforce the Patent Rights against any actual or suspected
                                         infringement of the Patent Rights with respect to the development or commercialization
                                         of a Competing Product in the Field and Territory by a third party or defend any declaratory
                                         action with respect thereto brought by such third party (a “Patent Action”),
                                         at its expense, and SOLÉSENCE shall provide all reasonable assistance to COLORESCIENCE
                                         in such Patent Action, including joining, at COLORESCIENCE’s reasonable expense,
                                         such Patent Action if necessary to maintain the Patent Action, or to seek additional
                                         or alternative damages or injunctive relief under such Patent Action.

 

		14.2.3.	If
                                         (i) COLORESCIENCE elects in writing not to bring or defend a Patent Action or (ii) within
                                         sixty (60) days following a written request by SOLÉSENCE to bring or defend a
                                         Patent Action and confirmation of facts reasonably supporting existence of such actual
                                         or suspected infringement with respect to the Patent Rights, COLORESCIENCE and its Affiliates
                                         and sublicensees fail to bring or defend a Patent Action or take other commercially reasonable
                                         action to protect the Patent Rights from such infringement, or to abate such infringement
                                         (which may in the discretion of COLORESCIENCE include, without limitation, negotiations
                                         for a settlement), then SOLÉSENCE or its Affiliates or other licensees shall have
                                         the right, but not the obligation, at its sole discretion, to institute a Patent Action
                                         in its own name using counsel of its choice, at its own expense, and COLORESCIENCE shall
                                         provide all reasonable assistance to SOLÉSENCE in such Patent Action, including
                                         joining, at SOLÉSENCE’s reasonable expense, such Patent Action if necessary
                                         to maintain the Patent Action, or to seek additional or alternative damages or injunctive
                                         relief under such Patent Action.

 

    18 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		14.2.4.	Any
                                         recovery received as a result of any Patent Action shall be used first to reimburse the
                                         Parties for their costs and expenses (including attorneys’ and professional fees)
                                         incurred in connection with such Patent Action (and not previously reimbursed), and any
                                         remaining amount of such recovery shall be awarded to the Party that brought or defended
                                         the suit; provided that if both Parties jointly bring or defend a Patent Action any amount
                                         recovered will be applied pro-rata (based on the agreed allocation of costs and expenses
                                         to be borne by each Party in such action or suit) for the costs and expenses with respect
                                         to such action or suit (including reasonable attorneys’ fees and costs) and the
                                         remaining amounts shall be similarly divided on a pro-rata basis unless otherwise agreed
                                         by the Parties.

 

		14.3.	Maintenance.

 

		14.3.1.	Maintenance
                                         of Existing Intellectual Property Registrations. SOLÉSENCE shall prosecute and
                                         maintain the Patent Rights and any trademark or copyright registrations related to any
                                         SOLÉSENCE Technology and any Products in each country in the Territory in which
                                         any such Patent Rights and any trademark or copyright registrations exist. In the event
                                         that SOLÉSENCE fails after reasonable written notice by COLORESCIENCE to prosecute
                                         or maintain any such Patent Rights and any trademark or copyright registrations, COLORESCIENCE
                                         shall have the right but not the obligation to do so in such instance, either in its
                                         own name or in the name of SOLÉSENCE.

 

		14.3.2.	Prosecution
                                         and Maintenance of Patent Applications for Improvements to SOLÉSENCE Technology.
                                         In the event that any Improvements to SOLÉSENCE Technology conceived or reduced
                                         to practice in the performance of this Agreement, the Parties shall consult each other
                                         in making a determination of whether to file one or more applications to obtain patents
                                         claiming such Improvement. SOLÉSENCE shall have the first right to file and prosecute
                                         patent applications claiming such Improvement. In the event that SOLÉSENCE elects
                                         not to file any patent applications for any such Improvement, COLORESCIENCE shall have
                                         the right, but not the obligation, to file and prosecute such patent application(s) in
                                         the name of SOLÉSENCE (or an Affiliates designated by SOLÉSENCE) and SOLÉSENCE
                                         and its Affiliates shall reasonably cooperate in any such efforts by COLORESCIENCE. In
                                         the event that SOLÉSENCE files but subsequently elects to abandon any patent application
                                         with respect to any such Improvement, COLORESCIENCE shall have the right, but not the
                                         obligation, to prosecute such patent application(s) in the name of SOLÉSENCE (or
                                         the SOLÉSENCE Affiliate named as the owner of record). In each such case, COLORESCIENCE
                                         shall provide SOLÉSENCE with written notice of its exercise of such right and
                                         SOLÉSENCE and its Affiliates shall reasonably cooperate in any such efforts by
                                         COLORESCIENCE. To the extent that any patent application covering any Improvement filed
                                         pursuant to this Section 14.3.2 matures into an issued patent, such patent shall be included
                                         in the Patent Rights and thereafter subject to Section 14.3.1.

 

    19 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		14.3.3.	Prosecution
                                         and Maintenance of Patent Applications for Joint IP. In the event that any Joint IP is
                                         conceived or reduced to practice in the performance of this Agreement, the Parties shall
                                         consult each other in making a determination of whether to file one or more applications
                                         to obtain patents claiming such Improvement. COLORESCIENCE shall have the first right
                                         to file and prosecute patent applications claiming such Joint IP, and SOLÉSENCE
                                         and its Affiliates shall reasonably cooperate in any such efforts by COLORESCIENCE. In
                                         the event that COLORESCIENCE elects not to file any patent applications for any such
                                         Joint IP, SOLÉSENCE shall have the right, but not the obligation, to file and
                                         prosecute such patent application(s) in the name of SOLÉSENCE and COLORESCIENCE
                                         (or an Affiliates designated by SOLÉSENCE or COLORESCIENCE) and COLORESCIENCE
                                         and its Affiliates shall reasonably cooperate in any such efforts by SOLÉSENCE.
                                         In the event that COLORESCIENCE files but subsequently elects to abandon any patent application
                                         with respect to any such Improvement, SOLÉSENCE shall have the right, but not
                                         the obligation, to prosecute such patent application(s) in the name of SOLÉSENCE
                                         and COLORESCIENCE (or the SOLÉSENCE or COLORESCIENCE Affiliate named as the owners
                                         of record). In each such case, SOLÉSENCE shall provide COLORESCIENCE with written
                                         notice of its exercise of such right and COLORESCIENCE and its Affiliates shall reasonably
                                         cooperate in any such efforts by SOLÉSENCE.

   

		15.	Notices

 

		15.1.	All
                                         notices in relation to a breach of this agreement or any demand notes to the other Party
                                         shall be in writing and shall be send to the following contact persons:

 

For
COLORESCIENCE:

 

	Name:	Ted Ebel
	 	 
	Function:	Chief Business Officer
	 	 
	Address:	2141 Palomar Airport Drive
	 	Carlsbad, CA 92011
	 	 
	Phone:	760-565-5736

 

For
SOLÉSENCE:

 

	Name:	Kevin Cureton
	 	 
	Function:	Chief Commercial Officer
	 	 
	Address:	1319 Marquette Drive
	 	Romeoville, Illinois 60446
	 	 
	Phone:	630-771-6733

 

		16.	Force
                                         Majeure

 

		16.1.	Deliveries
                                         or acceptance of the Product may be delayed or suspended by either of the Parties in
                                         the event of Act of God, war, riot, fire, explosion, accident, flood, sabotage, governmental
                                         laws, regulations, order or action, national defense requirements or any other event
                                         beyond the reasonable control of such Party (such event, a “Force Majeure Event”),
                                         any of which events prevent the manufacture, shipment, or acceptance or a shipment of
                                         the Product if, because of such event, SOLÉSENCE is unable to supply part or total
                                         demand for the Product, including due to scarcity of raw materials or if COLORESCIENCE,
                                         because of any such extent, is unable to accept part or total of quantity contracted
                                         for the affected Party shall be exempted to such extent from its obligations hereunder
                                         with respect to the particular delivery involved upon giving prompt notice of such event
                                         to the other Party. The other Party shall be likewise exempted from its corresponding
                                         obligations, but this Agreement shall otherwise remain unaffected.

 

    20 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		17.	Miscellaneous

 

		17.1.	ASSIGNMENT.
                                         This Agreement shall be binding upon and inure to the benefit of, the successors and
                                         permitted assigns of the parties. COLORESCIENCE shall have the right to assign this Agreement
                                         upon written notice to SOLÉSENCE. SOLÉSENCE shall have the right to assign
                                         this Agreement only to the acquirer of all or substantially all of its business to which
                                         this Agreement pertains, including all Intellectual Property Rights licensed hereunder.
                                         SOLÉSENCE shall not assign any Intellectual Property Rights hereunder except to
                                         an assignee who has assumed all of the rights and obligations under this Agreement. An
                                         assigning party shall give prompt notice of assignment to the other party. Any assignment
                                         not in compliance with this Section shall be null and void.

 

		17.2.	NO
                                         THIRD PARTY BENEFICIARIES. Nothing in this Agreement will confer any benefit or right
                                         upon any third party except for the Parties’ successors or permitted assignees.

 

		17.3.	RELATIONSHIP
                                         OF THE PARTIES. Nothing in this Agreement and no action taken by the Parties under this
                                         Agreement will constitute a partnership, joint venture or agency relationship between
                                         the Parties.

 

		17.4.	COUNTERPARTS.
                                         This Agreement may be executed in any number of counterparts, and by the Parties on separate
                                         counterparts, but will not be effective until each Party has executed at least one counterpart.
                                         Each counterpart will constitute an original of this Agreement, but all the counterparts
                                         together will constitute but one and the same agreement.

 

		17.5.	COSTS
                                         AND EXPENSES. Each Party will pay its own costs relating to the negotiation, preparation,
                                         execution and performance of this Agreement.

 

		17.6.	ENTIRE
                                         AGREEMENT. This Agreement, together with all Attachments and any other documents incorporated
                                         herein constitute the entire agreement of the Parties with respect to the subject matter
                                         in this Agreement, and supersede all prior and contemporaneous understandings, agreements,
                                         representations and warranties, both written and oral, with respect to the subject matter.
                                         Each Party acknowledges that, in entering into this Agreement, it has not relied on any
                                         statement, representation, warranty or agreement of the other Party other than as expressly
                                         contained in this Agreement.

 

		17.7.	AMENDMENTS.
                                         Any amendment of or variation to this Agreement must be in writing and signed by authorized
                                         representative(s) of both Parties.

 

		17.8.	WAIVER.
                                         No failure or delay by either Party in exercising any right or remedy provided under
                                         this Agreement or by law will constitute a waiver of that or any other right or remedy,
                                         nor will any single or partial exercise of any right or remedy preclude any other or
                                         further exercise of it or the exercise of any other right or remedy. No waiver under
                                         this Agreement is effective unless it is in writing and signed by authorized representative(s)
                                         of both Parties.

 

		17.9.	SEVERABILITY.
                                         If any provision in this Agreement, for any reason, is invalid, illegal or unenforceable,
                                         in whole or in part, in any jurisdiction, such invalidity, illegality or unenforceability
                                         will not affect any other provision of this Agreement or invalidate or render unenforceable
                                         such provision in any other jurisdiction. Upon a determination that any provision is
                                         invalid, illegal or unenforceable, the Parties will negotiate in good faith to modify
                                         this Agreement to effect the original intent of the Parties as closely as possible in
                                         a mutually acceptable manner in order that the transactions contemplated herein are consummated
                                         as originally contemplated to the greatest extent possible.

 

    21 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		17.10.	NOTICES.
                                         All notices provided in connection with this Agreement must be in writing and will be
                                         deemed to have been given (a) when delivered by hand; (b) when delivered if sent by an
                                         internationally recognized commercial courier; (c) on the third (3rd) day
                                         after the first post-mark of the sender’s postal service if sent by first class
                                         mail, postage prepaid (return receipt requested, if available). The notices must be sent
                                         to the respective Parties at the address of the contact person set forth in the “Description
                                         of the Parties” (or at such other address for a Party as may be specified in a
                                         notice given in accordance with this Section).

 

		17.11.	APPLICABILITY
                                         OF SECTION 365(N) OF THE BANKRUPTCY CODE. In the event SOLÉSENCE becomes a debtor
                                         under Title 11 of the U.S. Code (the “Bankruptcy Code”), this
                                         Agreement shall be deemed to be, for purposes of Section 365(n) of Title 11, a license
                                         to “Intellectual Property” as defined therein and COLORESCIENCE and its Affiliates,
                                         and each of their successors and assigns as licensees shall have the rights and elections
                                         as specified in the Bankruptcy Code. Specifically, if SOLÉSENCE, as a debtor-in-possession
                                         or a trustee-in-bankruptcy in a case under the Bankruptcy Code, rejects this Agreement,
                                         COLORESCIENCE and its Affiliates, successors and assigns may elect to retain their rights
                                         under this Agreement as provided in Section 365(n).

 

		17.12.	RESPONSIBILITY
                                         FOR SUPPLIER. SOLÉSENCE shall be responsible for any and all acts or omissions
                                         of its suppliers, manufacturers, contractors, agents, and Affiliates in each case where
                                         any action, or the corresponding responsibility, is required or permitted to be performed
                                         by either SOLÉSENCE or its suppliers, manufacturers, contractors, agents, and
                                         Affiliates and all such acts or omissions in such circumstances shall be deemed acts
                                         or omissions of SOLÉSENCE hereunder.

 

		17.13.	GOVERNING
                                         LAW. This Agreement shall be governed by and construed in accordance with the Laws of
                                         the United States and the State of Illinois, as applied to agreements entered into and
                                         to be performed entirely within Illinois between Illinois residents, without giving effect
                                         to the principles thereof relating to the conflicts of Laws. The Parties consent to the
                                         exclusive jurisdiction and venue of the State and Federal courts having within their
                                         jurisdiction Chicago, Illinois, and hereby agree to irrevocably waive all objections
                                         to personal jurisdiction, venue and forum non conveniens. The Parties exclude
                                         application of the United Nations Convention on Contracts for the International Sale
                                         of Goods. COLORESCIENCE AND SOLÉSENCE HEREBY IRREVOCABLY WAIVE THEIR RESPECTIVE
                                         RIGHTS TO TRIAL BY JURY IN RESPECT OF ANY DISPUTES ARISING UNDER OR RELATED TO THIS AGREEMENT.

 

Signature
page follows.

 

    22 

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

IN
WITNESS WHEREOF, this Amended and Restated Joint Development & Supply Agreement has been duly executed on behalf of the parties
as of the Effective Date.

 

	COLORESCIENCE, Inc. 	 	SOLÉSENCE, LLC	 
	 	 	 	 
	/s/
Ted Ebel 	 	/s/
Kevin Cureton 	 
	Name:
Ted Ebel	 	Name: Kevin Cureton	 
	Title:
Chief Business Officer	 	 Title: Chief Commercial Officer	 

  

     

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment. 

 

EXHIBIT
A

 

Annual Minimum Order Quantities

 

	 	Bridge
    Solution – TiO2	Innovation
    Active Solution – TiO2	Innovation Active Solution – ZnO

                                                                                

	Price per kg

                                                                                
	$[*]	$[*]	$[*]
	2017 Minimum Annual Purchases (kg)

                                                                                 
	All
    Obligations Fulfilled	0
	2018 Minimum Annual Purchases (kg)

                                                                                 
	[*]
    – combined	[*]
	2019 Minimum Annual Purchases (kg)

                                                                                 
	[*]
    – combined	[*]
	2020
    & beyond Minimum Annual Purchases (kg)	[*]%
    growth above the prior year volume, unless the prior year volume exceeded the minimums noted in which case [*]% minimum growth is sufficient	[*]%
    growth above the prior year volume, unless the prior year volume exceeded the minimums noted in which case [*]% minimum growth
    is sufficient

 

	Finished
    Products
	 	Finished
    Products A & B
	Price
    per Ounce	Finished
Product A: $[*] plus carton, insert, and packaging components, to increase by not more than [*]% per year 

        Finished
        Product B: $[*] plus carton, insert, and packaging components, to increase by not more than [*]% per year

         

	2018
    Minimum Order Quantity (units)	[*],
    if Solesence has filed and received approval by the Australian TGA to sell both Finished Product A and Finished Product B
    as registered sunscreens.  If not, the MOQ will be [*].  
	2019
    Minimum Order Quantity (units)	[*]
	2020
    Minimum Order Quantity (units)	[*]
	2021
    Minimum Order Quantity (units)	[*]
	2022
    and beyond Minimum Order Quantity (units)	[*]%
    annual increase from previous year for the duration of the Agreement

 

     

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

		●	Price
                                         per ounce for the Finished Products is the anticipated price per ounce for a “Full
                                         Face Product” anticipated to be developed by SOLÉSENCE assuming a per ounce
                                         size of [*] to [*] ounces. In the event that SOLÉSENCE develops a “Body
                                         Product”, such price per ounce will be lower. Both parties will work to identify
                                         the appropriate unit price regardless of format to enable Client to support a gross margin
                                         on such product of [*]% to [*]%, not including packaging cost.

 

     

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

EXHIBIT
B 

 

Product
Specifications

 

	TEST	PRODUCT	SPECIFICATION
	Actives
    Level (%)	Innovation Active – [*],

                                                                                 
	[*]
    – [*] %
	 	Innovation Active – [*]

                                                                                 
	[*]
    – [*] %
	 	Product A

                                                                                 
	[*]
    – [*]%
	Hydrophobicity	Innovation Actives

                                                                                 
	PASS
	Photostability	Innovation Actives

                                                                                 
	PASS
	USP
    monograph	 Innovation Actives

                                                                                 
	PASS
	Microbial
    Limits	 Product A, Product B

                                                                                 
	Less
    than [*]

 

 

     

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment. 

 

EXHIBIT
C 

 

Patent
Rights

 

	serial
    number	jurisdiction	filing
    date	title
	9,139,737	United
    states	11/21/2011	MULTIFUNCTIONAL
    COATED POWDERS AND HIGH SOLIDS DISPERSIONS

  

     

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

EXHIBIT
D 

 

Quality
Assurance

 

	TEST DESCRIPTION

                                                                                 
	METHOD	APPLICABLE
    PRODUCT
	Actives Level (%)

                                                                                 
	X-ray
    Fluorescence,	Bridge
    Actives, Innovation Active - [*], Product B
	Actives Level (%)

                                                                                 
	QA-01-625	Product
    A
	Hydrophobicity

                                                                                 
	QA-01-800	Bridge
    Actives, Innovation Actives
	Photostability

                                                                                 
	QA-01-1882	Bridge
    Active, Innovation Active [*]
	Photostability

                                                                                 
	QA-01-1883	Innovation
    Active [*]
	USP monograph

                                                                                 
	Current
    USP monograph	Bridge
    Active, Innovation Actives
	Microbial
    Limits	USP 
	Bridge
    Active, Innovation Active, Product A, Product B

  

     

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment.

 

EXHIBIT
E 

 

SOLÉSENCE
Trademarks

 

Solésence® 

 

     

     

    

 

Portions
of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been
filed separately with the Securities and Exchange Commission together with such request for confidential treatment. 

 

EXHIBIT
F

 

Reserved Rights

 

		I.	Any
                                         Environmental Protection Product containing (i) a prescription (as defined by the U.S.
                                         FDA) active ingredient and (ii) the Solésence Technology. 

 

		II.	Any
                                         Environmental Protection Product comprising an over-the-counter (as defined by the U.S.
                                         FDA) active ingredient and the Solésence Technology, wherein such over-the-counter
                                         active ingredient is not permitted under the U.S. FDA sunscreen monograph (Sunscreen
                                         Drug Products for Over-the-Counter Human Use) to be used in combination with sunscreen
                                         active ingredients within the United States.

 

		III.	Any
                                         Environmental Protection Product wherein the primary active ingredient is a therapeutic
                                         active ingredient that is enhanced when used in combination with the Solésence
                                         Technology.

 

		IV.	Any
                                         product supplied to [*]
                                         or [*],
                                         except for products that utilize the Exclusive Application or use or contain [*]
                                         or [*].
                                         

 

		V.	Any
                                         product intended for spray application to human skin.EX-4.2

 Exhibit 4.2 

MAGENTA THERAPEUTICS, INC. 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

April 2, 2018 
  

 TABLE OF CONTENTS 

 

													
	 	 	 	 	 	 	 	 	 	  	Page	 
	 1.
	 		 	Definitions	  	 	1	 
				
	 2.
	 		 	Registration Rights	  	 	5	 
						
		 		 		 	 2.1
	 	Demand Registration	  	 	5	 
		 		 		 	 2.2
	 	Company Registration	  	 	7	 
		 		 		 	 2.3
	 	Underwriting Requirements	  	 	7	 
		 		 		 	 2.4
	 	Obligations of the Company	  	 	8	 
		 		 		 	 2.5
	 	Furnish Information	  	 	10	 
		 		 		 	 2.6
	 	Expenses of Registration	  	 	10	 
		 		 		 	 2.7
	 	Delay of Registration	  	 	10	 
		 		 		 	 2.8
	 	Indemnification	  	 	11	 
		 		 		 	 2.9
	 	Reports under Exchange Act	  	 	13	 
		 		 		 	 2.10
	 	Limitations on Subsequent Registration Rights	  	 	13	 
		 		 		 	 2.11
	 	“Market Stand-off” Agreement	  	 	13	 
		 		 		 	 2.12
	 	Restrictions on Transfer	  	 	14	 
		 		 		 	 2.13
	 	Termination of Registration Rights	  	 	16	 
					
	 3.
	 		 		 	 Information
	  	 	16	 
						
		 		 		 	 3.1
	 	Delivery of Financial Statements	  	 	16	 
		 		 		 	 3.2
	 	Inspection	  	 	17	 
		 		 		 	 3.3
	 	Termination of Information Rights	  	 	17	 
		 		 		 	 3.4
	 	Confidentiality	  	 	18	 
					
	 4.
	 		 		 	 Rights to Future Stock Issuances
	  	 	18	 
						
		 		 		 	 4.1
	 	Right of First Offer	  	 	18	 
		 		 		 	 4.2
	 	Termination	  	 	20	 
					
	 5.
	 		 		 	 Additional Covenants
	  	 	20	 
						
		 		 		 	 5.1
	 	Insurance	  	 	20	 
		 		 		 	 5.2
	 	Employee Agreements	  	 	20	 
		 		 		 	 5.3
	 	Employee Vesting	  	 	20	 
		 		 		 	 5.4
	 	Matters Requiring Investor Director Approval	  	 	21	 
		 		 		 	 5.5
	 	Meetings of the Board of Directors; Committees	  	 	21	 
		 		 		 	 5.6
	 	Successor Indemnification	  	 	22	 
		 		 		 	 5.7
	 	Board Expenses	  	 	22	 
		 		 		 	 5.8
	 	Directors’ Liability and Indemnification	  	 	22	 
		 		 		 	 5.9
	 	Right to Conduct Activities	  	 	23	 
		 		 		 	 5.10
	 	Termination of Covenants	  	 	23	 

  
 i 

									
	 6.
	 	 Miscellaneous
	  	 	24	 
				
		 	 6.1
	  	Successors and Assigns	  	 	24	 
		 	 6.2
	  	Governing Law	  	 	24	 
		 	 6.3
	  	Counterparts; Facsimile	  	 	24	 
		 	 6.4
	  	Titles and Subtitles	  	 	24	 
		 	 6.5
	  	Notices	  	 	24	 
		 	 6.6
	  	Amendments and Waivers	  	 	25	 
		 	 6.7
	  	Severability	  	 	25	 
		 	 6.8
	  	Aggregation of Stock	  	 	26	 
		 	 6.9
	  	Additional Investors	  	 	26	 
		 	 6.10
	  	Entire Agreement	  	 	26	 
		 	 6.11
	  	Delays or Omissions	  	 	26	 
		 	 6.12
	  	Submission to Jurisdiction	  	 	26	 

  
 ii 

 MAGENTA THERAPEUTICS, INC. 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of April 2, 2018, by and
among Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively, the
“Investors”. 
 RECITALS: 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A
Preferred Stock, Series B Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer and other rights pursuant to an Amended and Restated Investors’
Rights Agreement dated April 21, 2017 between the Company and such Investors (the “Prior Agreement”); 

WHEREAS, the Existing Investors are holders of a majority of the Registrable Securities of the Company (as defined in the Prior
Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and 

WHEREAS, certain of the Investors are parties to that certain Series C Preferred Stock Purchase Agreement of even date herewith between
the Company and such Investors (as the same may be amended or restated from time to time, the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution
and delivery of this Agreement by such Investors, Existing Investors holding a majority of the Registrable Securities, and the Company. 

NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who or which, directly or indirectly, controls,
is controlled by, or is under common control with such specified Person, including, without limitation, any partner, officer, director, member or employee of such specified Person and any venture capital fund now or hereafter existing that is
controlled by or under common control with one or more general partners or managing members of, or shares the same management company with, such specified Person. Third Rock Ventures IV, L.P., Atlas Venture Fund X, L.P. and the Company shall not be
deemed to be Affiliated for the purposes of this Agreement. 
 1.2 “Board of Directors” means the Company’s Board of
Directors. 
 1.3 “Business Day” means a day (i) other than Saturday or Sunday and (ii) on which commercial banks
are open for business in Boston, Massachusetts. 

  
 1 

 1.4 “Certificate of Incorporation” means the Company’s Third Amended and
Restated Certificate of Incorporation, as the same may be amended, restated or otherwise modified from time to time. 
 1.5 “Common
Stock” means shares of the Company’s common stock, par value $0.001 per share. 
 1.6 “Competitor” means a
Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in activities or a line of business that are
directly or indirectly competitive with Company’s business as then conducted or as then proposed to be conducted, but shall not include (i) any financial investment firm or collective investment vehicle solely by virtue of its ownership
(and/or its Affiliates’ ownership) of an equity interest in any Competitor held solely for investment purposes, (ii) as of the date hereof, Be The Match BioTherapies, LLC, (iii) GV 2016, L.P. or any of its affiliated funds, solely as
a result of any affiliation between such fund and Alphabet Inc. (including any Affiliate of Alphabet Inc.), (iv) Casdin Partners Master Fund, LP or (v) any of the LP Investors. 

1.7 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under
the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a
material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities
Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.8 “Deemed Liquidation Event” shall have the meaning given to such term in the Certificate of Incorporation. 

1.9 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.10 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.11 “Excluded Registration”
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; or
(iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities. 

  
 2 

 1.12 “Form S-1” means such form
under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.13 “Form S-3” means such form under the Securities Act as in effect on the
date hereof, any successor registration form under the Securities Act subsequently adopted by the SEC or any other registration form under the Securities Act adopted by the SEC that permits incorporation of substantial information by reference to
other documents filed by the Company with the SEC. 
 1.14 “GAAP” means generally accepted accounting principles in the
United States. 
 1.15 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.16 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.17 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.18 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.19 “Key Employee” shall have the definition ascribed to it under the Purchase Agreement. 

1.20 “LP Investors” means, collectively, each of PH Investments, LLC, SCubed Capital, LLC, Sobrato Family Holdings, LLC,
Harvard Management Private Equity Corporation, Portland Magenta EP, LLC, Portland Magenta PIA, LLC and Fifth Avenue Private Equity 14 LLC. 

1.21 “Major Investor” means (i) any Investor other than an LP Investor that, individually or together with such
Investor’s Affiliates, holds at least 800,000 shares of Registrable Securities determined as of the date hereof (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization
occurring after the date of this Agreement) and (ii) each LP Investor for so long as such LP Investor holds at least fifty percent (50%) of the shares of Series C Preferred Stock held by it immediately following the Closing (as defined in the
Purchase Agreement). 
 1.22 “New Securities” means, collectively, equity securities of the Company, whether or not
currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

  
 3 

 1.23 “Person” means any individual, corporation, partnership, trust, limited
liability company, association or other entity. 
 1.24 “Preferred Directors” means, collectively, the Series A Directors
and the Series B Director. 
 1.25 “Preferred Stock” means, collectively, the Series A Preferred Stock, the Series B
Preferred Stock and the Series C Preferred Stock. 
 1.26 “QPO” shall have the meaning set forth in the Certificate
of Incorporation. 
 1.27 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of
the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, held by the Major Investors or acquired by the Major
Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for
or in replacement of, the shares referenced in clauses (i) and (ii) above; provided that, (A) in all cases, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are
not assigned pursuant to Section 6.1 shall cease to be Registrable Securities, and (B) for purposes of Section 2, any Registrable Securities for which registration rights have terminated
pursuant to Section 2.13 of this Agreement shall cease to be Registrable Securities. 
 1.28 “Registrable
Securities then outstanding” means the number of shares at a point in time determined by adding the number of shares of outstanding Common Stock that are Registrable Securities at such time and the number of shares of Common Stock
issuable (directly or indirectly) at such time pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.29 “Restricted Securities” means the securities of the Company required to bear the legend set forth in
Section 2.12(b) hereof. 
 1.30 “SEC” means the Securities and Exchange Commission. 

1.31 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act, or any successor provisions. 

1.32 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act, or any successor provisions. 

1.33 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.34 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

  
 4 

 1.35 “Series A Directors” means the directors of the Company that the holders of
record of the Series A Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation. 
 1.36 “Series B
Director” means the director of the Company that the holders of record of the Series B Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation. 

1.37 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.001 per share. 

1.38 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.001 per share. 

1.39 “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.001 per share. 

1.40 “Stockholders Agreement” means the Second Amended and Restated Stockholders Agreement dated as of the date hereof, by
and among the Company, the Investors, and Key Holders (as defined therein), as the same may be amended, restated or otherwise modified from time to time. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. Beginning upon the earlier of (i) five (5) years after the date of
this Agreement or (ii) six (6) months after the effective date of the registration statement for the IPO, if the Company receives a request from Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that
the Company file a Form S-1 registration statement with respect to at least twenty-five percent (25%) of the Registrable Securities then outstanding, having the anticipated aggregate offering amount of
at least $3.0 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as
soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all
Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to
the Company within twenty (20) days after the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%) 

  
 5 

 
of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities
of such Holders having an anticipated aggregate offering amount, net of Selling Expenses, of at least $1.0 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all
Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form
S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to
the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer or other most senior executive officer then in office stating that in the good faith judgment of the Board of Directors it would be materially
detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would
(i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business
purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any
time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the
Company may not invoke this right more than once in any twelve (12) month period, nor shall the Company invoke this right more than twice in all periods; and provided further that the Company shall not register any securities for its own
account or that of any other stockholder during either one hundred twenty (120) day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(a) (i) if it delivers notice to the Holders within thirty (30) days after any registration request of its intent to file a registration statement for a public offering within ninety (90) days;
(ii) during the period that is one hundred eighty (180) days after commencing a Company-initiated registration; (iii) after the Company has effected two (2) registrations pursuant to Section 2.1(a); or
(iv) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to
Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) if the Company has effected two (2) registrations
pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration (other than as a result of a
material adverse change to the Company), elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration
statement shall be counted as “effected” for purposes of this Section 2.1(d). 

  
 6 

 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than
Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration
shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding
any other provision of this Section 2.3, if the managing underwriter(s) advise the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating
Holders shall so advise all Holders that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders, including the Initiating Holders, in
proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder, or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable
Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions,
the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 
 (b) In connection with
any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success

  
 7 

 
of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to
be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities,
including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to
be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by
each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of
shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be
sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless
such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in
this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates
of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling
Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this
sentence. 
 (c) For purposes of Section 2.1, a registration shall not be counted as “effected” if, as
a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a) and (b), less than the total number of Registrable Securities that Holders have requested to be included in such registration
statement are actually included. 
 2.4 Obligations of the Company. 

Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall,
as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration statement with respect to such Registrable
Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement
effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day
period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of the Company, from selling any securities included in such 

  
 8 

 
registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or
delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to one hundred eighty (180) days, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and
the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders,
all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such
seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

  
 9 

 (i) notify each selling Holder, promptly after the Company receives notice thereof, of the time
when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 2.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $60,000, of one counsel for the selling Holders (“Selling Holder Counsel”) selected by the Holders of a majority in interest of the Registrable Securities, shall be borne and paid by the Company;
provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of
the Holders of a majority in interest of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn
registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be;
provided further that if, at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have
withdrawn the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to
Section 2.1(a) or Section 2.1(b), as the case may be. All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid
by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 
 2.7 Delay of
Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or
implementation of this Section 2. 

  
 10 

 2.8 Indemnification. If any Registrable Securities are included in a registration
statement under this Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each
Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person
any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be
unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such
Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person
of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on
behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not
apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall any indemnity
or contribution under this Section 2.8(b) or under Section 2.8(d) exceed, in the aggregate, the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such
Holder), except in the case of fraud or willful misconduct by such Holder. 
 (c) Promptly after receipt by an indemnified party under this
Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the
extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an
indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the 

  
 11 

 
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in
such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Section 2.8. 
 (d) To provide for just and
equitable contribution to joint liability under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this
Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such
indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of
any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may
be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted
in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price
of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be
entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when
combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case
of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification
and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall
survive the termination of this Agreement. 

  
 12 

 2.9 Reports under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as
those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the
prior written consent of the Holders of a majority in interest of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or
prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of
such securities will not reduce the number of the Registrable Securities of the Holders that are included or (ii) to demand registration of any securities held by such holder or prospective holder; provided that this limitation shall not
apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 
 2.11
“Market Stand-off” Agreement. 
 Each Holder hereby
agrees that, if required by the managing underwriter, it will not, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to
exceed one 

  
 13 

 
hundred eighty (180) days), or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution
of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) (i) lend;
offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of
Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any
swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of
Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an
underwriting agreement, and shall be applicable to the Holders only if all officers, directors, and stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into
Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this
Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the
underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. The Company agrees to use its reasonable efforts to obtain the agreement of
the managing underwriter to periodic early releases of portions of the securities subject to such lock-up agreements upon the request of a Holder to such early release, provided that in the event of any early
release, all Holders will be released on a pro rata basis from such agreements. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders
subject to such agreements, based on the number of shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed
purchaser, pledgee, or transferee of the Preferred Stock or the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

  
 14 

 (b) Each certificate or instrument representing (i) the Preferred Stock, (ii) the
Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall
(unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of each certificate or instrument representing Restricted Securities, by acceptance thereof, agrees to comply in all respects
with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed
transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in
sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the
Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or
transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to
the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such
Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration provided that each transferee agrees in writing to be subject to the terms of this Section 2.12 or (y) in any transaction in compliance with SEC
Rule 144. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in
Section 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with
any provisions of the Securities Act. 

  
 15 

 2.13 Termination of Registration Rights. The right of any Holder to request registration
or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares
without limitation during a three-month period without registration; and 
 (c) the fifth
(5th) anniversary of the IPO. 
 3. Information. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor the required items listed below, provided that
the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company. 
 (a) as soon as
practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and
(iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally or regionally recognized standing selected by the Company and
approved by the Board of Directors; 
 (b) as soon as practicable but in any event within forty-five (45) days after the end of each
quarter of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in
accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with
GAAP); 
 (c) as soon as practicable, but in any event within thirty (30) days after the end of each month, an unaudited income
statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be
subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(d) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the
Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or
exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for
issuance, if any, all in sufficient detail as to permit each Major Investor to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being
true, complete, and correct; 

  
 16 

 (e) as soon as practicable, but in any event thirty (30) days before the end of each fiscal
year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for
such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 
 (f) such other information
relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this
Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or highly confidential information (unless covered by an enforceable confidentiality agreement, in a form
reasonably acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply
with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively
employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The
Company shall permit each Major Investor (provided that such Major Investor is not a Competitor of the Company as reasonably determined by the Board of Directors), at such Major Investor’s expense, to visit and inspect the Company’s
properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided,
however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless
covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Termination of Information Rights. The covenants set forth in Sections 3.1 and 3.2 shall terminate and be of no
further force or effect upon the earliest to occur of (i) immediately before, but subject to, the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of
the Exchange Act, or (iii) upon a Deemed Liquidation Event resulting in proceeds to the Investors paid solely in cash or publicly traded securities on a nationally recognized securities exchange or marketplace (e.g., the New York Stock Exchange
and the Nasdaq Stock Market). 

  
 17 

 3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and
will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention
to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor), (b) is or has
been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, advisors and other professionals (collectively,
“Representatives”) to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser agrees to be bound by the provisions of this Section 3.4; (iii) in the ordinary course of business to any existing or prospective, direct or indirect, Affiliate, partner, member, stockholder, or wholly
owned subsidiary of such Investor and any Representatives, employees or Affiliates of any of the foregoing, provided that such Investor informs any such recipient that such information is confidential and directs such recipient to maintain the
confidentiality of such information (each of the foregoing Persons, a “Permitted Disclosee”); or (iv) as may otherwise be required by law or securities exchange regulations or at the request of a regulatory authority, provided
that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. Furthermore, nothing contained herein shall prevent any Investor or any Permitted Disclosee from
entering into any business, entering into any agreement with a third party, or investing in or engaging in investment discussions with any other company (whether or not competitive with the Company), provided that such Investor or Permitted
Disclosee does not, except as permitted in accordance with this Section 3.4, disclose any proprietary or confidential information of the Company in connection with such activities; and provided further, each Investor may identify the Company
and the value of such Investor’s security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies and respond to routine examinations, demands, requests or reporting
requirements of any regulator without prior notice to or consent from the Company. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor, provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor
of the Company. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions as it deems appropriate, provided that each such Affiliate (x) is
not a Competitor of the Company as reasonably determined by the Board of Directors, and (y) agrees to enter into this Agreement and the Stockholders Agreement of even date herewith among the Company, the Investors and the other parties named
therein, as an “Investor” under each such agreement. 

  
 18 

 (a) The Company shall give notice (the “Offer Notice”) to each Major Investor,
stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total number of shares of Common Stock of the Company then
outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects
to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such
notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which such Major Investors were entitled to
subscribe, but that were not subscribed for by the Major Investors, which is equal to the proportion that the Common Stock issued and held, or issuable upon conversion of Preferred Stock and any other Derivative Securities then held, by such Fully
Exercising Investor bears to the number of shares of Common Stock issued and held, or issuable (directly or indirectly) upon conversion of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish
to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of one hundred twenty (120) days after the date that the Offer Notice is given and the date of initial sale
of New Securities pursuant to Section 4.1(c). 
 (c) If fewer than all New Securities referred to in the Offer
Notice are elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in
Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer
Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Section 4.1. 

(d) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as
defined in the Certificate of Incorporation), (ii) any shares of Series C Preferred Stock sold pursuant to the Purchase Agreement, and (iii) shares of Common Stock issued in the IPO. 

(e) The rights of the Major Investors to purchase New Securities under this Section 4.1 may be modified or waived
in accordance with Section 6.6; provided, however, 

  
 19 

 
that in the event such rights to purchase New Securities under this Section 4.1 are waived and any Major Investor(s) purchase New Securities, the Company shall give
notice to the other Major Investors within thirty (30) days after the initial issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each such other Major Investor shall have twenty
(20) days from the date such notice is given to elect to purchase on similar terms and conditions in a subsequent closing up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s
percentage-ownership position, calculated as set forth in Section 4.1(b) before giving effect to the issuance of such New Securities. 

4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect
upon the earliest to occur of (i) immediately before, but subject to, the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act with
its Common Stock listed on the NYSE or NASDAQ or (iii) upon a Deemed Liquidation Event. 
 5. Additional Covenants. 

5.1 Insurance. The Company has obtained, or shall obtain within 90 days of the date of this Agreement, from financially sound and
reputable insurers Directors and Officers Errors and Omissions insurance in an amount satisfactory to the Board of Directors, including a majority of the Preferred Directors then serving on the Board of Directors, and will use commercially
reasonable efforts to cause such insurance policy to be maintained until such time as the Board of Directors (including the affirmative vote of all of the Preferred Directors then serving on the Board of Directors) determines that such insurance
should be discontinued. 
 5.2 Employee Agreements. The Company will cause (a) each individual now or hereafter employed by it
or by any subsidiary (or engaged by the Company or any subsidiary as an individual consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment
agreement and (b) each Key Employee or Intellectual Property Employee (as defined in the Purchase Agreement) to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of
Directors, including a majority of the Preferred Directors then serving on the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or
any restricted stock agreement between the Company and any employee, without the approval by the Board of Directors, including a majority of the Preferred Directors then serving on the Board of Directors. 

5.3 Employee Vesting. Unless otherwise approved by the Board of Directors, which approval shall include a majority of the Preferred
Directors then serving on the Board of Directors, all current and future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall
be required to execute restricted stock or option agreements, as applicable, providing for (a) vesting of shares, not faster than over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve
(12) months of continued employment or service, and the remaining shares vesting in equal quarterly installments over 

  
 20 

 
the following three (3) years, and (b) a market stand-off provision substantially similar to that in Section 2.11. In
addition, unless otherwise approved by the Board of Directors, including a majority of the Preferred Directors then serving on the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers of
shares of Common Stock until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Matters Requiring Investor Director Approval. So long as any shares of Preferred Stock remain outstanding, the Company hereby
covenants and agrees with each of the Investors that it shall not, without first obtaining the approval of the Board of Directors, which approval must include the affirmative vote of a majority of the Preferred Directors then serving on the Board of
Directors: 
 (a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary
or other corporation, partnership, or other entity unless it is wholly owned by the Company; 
 (b) create any subsidiary; 

(c) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the
Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(d) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (e) make any investment inconsistent with any
investment policy approved by the Board of Directors; 
 (f) incur indebtedness in excess of $200,000 in the aggregate that is not covered
by the Budget, other than trade credit incurred in the ordinary course of business; 
 (g) otherwise enter into or be a party to any
transaction with any director, officer or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person; 

(h) hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to executive
officers; or 
 (i) change the principal business of the Company, or enter into a new line of business, or exit the existing line of
business of the Company. 
 5.5 Meetings of the Board of Directors; Committees. Unless otherwise determined by the vote of at
least a majority of the directors then in office, the Board of Directors shall meet at least four (4) times per year, and at least once per quarter, in accordance with an agreed-upon schedule. Each
non-employee director shall be entitled in such person’s discretion to be a member of any committee of the Board of Directors. 

  
 21 

 5.6 Successor Indemnification. If the Company or any of its successors or
assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and
assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s By-laws, the Certificate of Incorporation, or elsewhere, as the case may be. 
 5.7 Board
Expenses. The Company shall reimburse the non-employee directors for all reasonable out-of-pocket expenses incurred
(consistent with the Company’s policies) in connection with their role as a director of the Company. 
 5.8
Directors’ Liability and Indemnification. 
 (a) The Certificate of Incorporation and By-laws (as such By-laws of the Company may be amended from time to time) shall provide (i) for limitation of the liability of directors to the maximum extent permitted
by law, and (ii) for indemnification of directors for acts on behalf of the Company to the maximum extent permitted by law. In the event any suit is filed or claim is asserted against a director or former director of the Company as a result of
such director’s or former director’s service on the Board of Directors, the Company will provide such director or former director access to all records and files of the Company as he or she may reasonably request in defending against or
preparing to defend against any such suit or claim. 
 (b) The Company hereby acknowledges that one or more of the Preferred Directors may
have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Fund Indemnitors”) for alleged acts or omissions in their
capacities as directors of the Company. The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to any such director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide
indemnification for the same expenses or liabilities incurred by such director are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by such director and shall be liable for the full amount of all expenses,
judgments, penalties, fines and amounts paid in settlement by or on behalf of any such director to the extent legally permitted and as required by the Certificate of Incorporation or By-laws of the Company (or
any agreement between the Company and such director), without regard to any rights such director may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all
claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such director with respect to
any claim for which such director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the
rights of recovery of such director against the Company. 

  
 22 

 5.9 Right to Conduct Activities. The Company hereby agrees and acknowledges that each of
Third Rock Ventures IV, L.P., Atlas Venture Fund X, L.P., GV 2016, L.P., Partners Innovation Fund LLC, Be The Match BioTherapies, LLC, Access Industries Holdings LLC, Casdin Partners Master Fund, LP and each LP Investor (in each case, together with
its Affiliates) and funds advised by Eventide Asset Management (each, collectively, an “Investing Entity”) invests in or may hereafter invest in one or more other portfolio companies (“PortCos”), some of which may
be deemed competitive with the Company’s business (as currently conducted or as currently proposed to be conducted). The Company hereby agrees that (a) no Investing Entity shall be deemed to be a Competitor of the Company in respect of any
investment such Investing Entity makes in any PortCo, and (b) to the extent permitted under applicable law, no Investing Entity shall be liable to the Company for any claim arising out of, or based upon, (i) the investment by such
Investing Entity in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of such Investing Entity to assist any such competitive company, whether or not such action was taken as a member
of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability
associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the
Company. 
 5.10 ERISA Matters. The Company will exercise its reasonable best efforts to ensure that, at all times during which any
Purchaser holds any Preferred Stock or Common Stock, the assets of the Company will not be deemed to be “plan assets” for purposes of Employee Retirement Income Security Act of 1974 (“ERISA”). The Company agrees to
provide notice, in writing, to each Purchaser as soon as is reasonably practicable upon determining that the assets of the Company are reasonably likely to be deemed “plan assets” for purposes of ERISA. 

5.11 Publicity. The Company may not make use of any Investor’s name on its website, via press release or other similar
communication without the prior consent of such Investor, which consent may be delivered to the Company via email. 
 5.12 Termination of
Covenants. The covenants set forth in this Section 5, except for Sections 5.6 and 5.8, shall terminate and be of no further force or effect upon the earliest to occur of (i) immediately before but subject
to the consummation of a QPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act with its Common Stock listed on the NYSE or NASDAQ, or (iii) upon a Deemed
Liquidation Event. 

  
 23 

 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i) is an Affiliate, member, retired partner, retired member or stockholder of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one
or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 50,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other
recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such
rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of
Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate, limited partner, retired partner, member,
retired member, or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and
with those of the transferring Holder and its Affiliates; provided further that all transferees who would not qualify individually for assignment of rights shall have a single
attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure
to the benefit of and are binding upon the respective successors and permitted assignees of the parties, including without limitation, the Investor’s Affiliates. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware,
without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3 Counterparts; Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile signature, email signature, or other form of electronic transmission. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent, if sent by confirmed electronic mail or facsimile and sent during normal business hours of the
recipient, and if not so confirmed, then on the next Business Day; (c) five (5) days after having been sent by registered or certified mail, 

  
 24 

 
return receipt requested, postage prepaid; or (d) one (1) Business Day after the Business Day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next
Business Day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of
the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the
Company, a copy, which shall not constitute notice, shall also be sent to Mitchell S. Bloom and William D. Collins at Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least sixty percent (60%) of the Registrable Securities then outstanding; provided
that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of
Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the
foregoing, (i) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver
applies to all Investors in the same fashion, (ii) any waiver of the provisions of Section 4 shall be effective only if all Major Investors that have rights under Section 4 are provided the
opportunity to participate in such offering to the same extent (on a percentage basis) of their pro rata share and on similar terms as the other Major Investors who are participating in such offering (including, but not limited to, through a rights
offering completed in accordance with the procedures set forth in Section 4.1(e)), and (iii) the provisions of Section 3 and Section 4 may be amended and the observance of any term
thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Major Investors holding at least sixty percent (60%) of the Registrable Securities then held by all
Major Investors. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver
effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this
Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 

  
 25 

 6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by
Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated Person may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if after the date hereof the Company issues
additional shares of the Preferred Stock to a Person who is not already a party to this Agreement (any such person, a “New Investor”), as a condition to the issuance of such shares the Company shall require that such New Investor
become a party to this Agreement by executing and delivering a counterpart signature page or joinder agreement to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the
Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. Schedule A to
this Agreement shall be updated, as applicable, to reflect the issuance of Preferred Stock and Common Stock, respectively, to a New Investor. 

6.10 Entire Agreement. Upon effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated to read in its
entirety as set forth in this Agreement. This Agreement (including the Schedules hereto) constitutes the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral
agreement relating to the subject matter hereof existing between the parties (including the Prior Agreement) are expressly canceled. 

6.11 Delays or Omissions. Except as set forth in Section 2.1(c) (with respect to the Company’s failure
to object promptly to a transfer), no delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or
remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.12 Submission to Jurisdiction. The parties hereto submit to the exclusive jurisdiction of any federal or state court located within
the Commonwealth of Massachusetts over any dispute arising out of or relating to the Agreement or any of the transactions contemplated hereby and each party hereby agree that all claims in respect of such dispute or any suit, action or proceeding
related thereto may be heard and determined in such courts. The parties waive, to the fullest extent permitted by applicable law, any objection which they may not or hereafter have to the laying of venue of any such dispute brought in such court or
any defense of inconvenient forum for the maintenance of such dispute. Each of the parties hereto agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

[Remainder of Page Intentionally Left Blank] 

  
 26 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 COMPANY:
  

	 MAGENTA THERAPEUTICS, INC.
  

	By:	 	 /s/ Jason Gardner

	Name: Jason Gardner
	Title: President and Chief Executive Officer

 [Signature Page to Second Amended and Restated Investors’ Rights Agreement] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 THIRD ROCK VENTURES IV, L.P.
  

	By: Third Rock Ventures GP IV, L.P., its general partner
	 By: TRV GP IV, LLC, its general partner
  

	By:	 	 /s/ Kevin Gillis

	Name:	 	Kevin Gillis
	Title:	 	CFO/Partner

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 ATLAS VENTURE FUND X, L.P.
  

	By: Atlas Venture Associates X, L.P.
	 Its General Partner
  

	By: Atlas Venture Associates X, LLC
	 Its General Partner
  

	By:	 	 /s/ Ommer Chohan

	Name:	 	Ommer Chohan
	Title:	 	CFO

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 GV 2016, L.P.
  

	By: GV 2016 GP, L.P., its General Partner
	 By: GV 2016 GP, L.L.C., its General Partner

 

	By:	 	 /s/ Daphne M. Chang

		 	Name: Daphne M. Chang
		 	Title: Authorized Signatory

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 BE THE MATCH BIOTHERAPIES, LLC
  

	By:	 	 /s/ Amy Ronneberg

		 	Name: Amy Ronneberg
		 	Title:   President

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 ACCESS INDUSTRIES HOLDINGS LLC
  

	By:	 	Access Industries Management, LLC,
		 	 Its Manager
  

	By:	 	 /s/ Peter L. Theorén

		 	Name: Peter L. Theorén
		 	Title:   Executive Vice President

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 PARTNERS INNOVATION FUND, LLC
  

	By:	 	 /s/ Roger Kitterman

		 	Name: Roger Kitterman
		 	 Title:   Managing Partner
  

	 PARTNERS INNOVATION FUND II, L.P.
  

	By:	 	 /s/ Roger Kitterman

		 	Name: Roger Kitterman
		 	Title:   Managing Partner

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 CASDIN PARTNERS MASTER FUND, LP
  

	 By: Casdin Partners GP, LLC, its General Partner

 

	By:	 	 /s/ Eli Casdin

		 	Name: Eli Casdin
		 	 Title:   Managing Partner
  

	 CASDIN VENTURE OPPORTUNITIES FUND, L.P.

 

	By:	 	 Casdin Partners GP, LLC, its General Partner
  

	By:	 	 /s/ Eli Casdin

		 	Name: Eli Casdin
		 	Title:   Managing Partner

 [Signature Page to Second Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.

 

	By:	 	 /s/ Scott A. Brown

		 	Name: Scott A. Brown
		 	Title:   Vice President, General Counsel

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	By:	 	 /s/ Robert W. Postma

		 	 Name: Robert W Postma

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 MUTUAL FUND SERIES TRUST, ON BEHALF OF EVENTIDE HEALTHCARE & LIFE SCIENCES FUND

 

	By:	 	 /s/ Erik Naviloff

	Name:	 	Erik Naviloff
	Title:	 	Treasurer
	  
 INVESTOR:

 

	 MUTUAL FUND SERIES TRUST, ON BEHALF OF EVENTIDE GILEAD FUND

 

	By:	 	 /s/ Erik Naviloff

	Name:	 	Erik Naviloff
	Title:	 	Treasurer

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 EcoR1 CAPITAL FUND, LP
  

	 By: EcoR1 Capital LLC, its General Partner

 

	By:	 	 /s/ Oleg Nodelman

		 	Name: Oleg Nodelman
		 	Title:   Manager
	  
 EcoR1 CAPITAL FUND QUALIFIED, LP

 

	By:	 	EcoR1 Capital LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

		 	Name: Oleg Nodelman
		 	Title:   Manager

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 HARVARD MANAGEMENT PRIVATE EQUITY CORPORATION

 

	By:	 	 /s/ Richard W. Slocum

		 	Name: Richard W. Slocum
		 	 Title:   Authorized Signatory
  

	By:	 	 /s/ Marcus Loveland

		 	Name: Marcus Loveland
		 	Title:   Authorized Signatory

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 Fifth Avenue Private Equity 14 LLC
  

	By:	 	 /s/ Charles D. Bryceland

	Name: Charles D. Bryceland
	Title: Managing Director

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 SCubed Capital, LLC
  

	By:	 	 /s/ Mark Stevens

	Name: Mark Stevens
	Title: Managing Partner

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 PH Investments, LLC
  

	By:	 	 /s/ John W. Vander Vort

		 	Name: John W. Vander Vort
		 	Title:   Managing Director

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

Sobrato Family Holdings, LLC
  

	By:	 	 /s/ Matthew W. Sonsini

	Name: Matthew W. Sonsini
	Title: Chief Investment Officer, on behalf of Sobrato Family Holdings, LLC

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:
  

	 Portland Magenta EP, LLC
  

	By:	 	 Partners HealthCare Master Trust for
 ERISA
Assets, its managing member

		
	By:	 	 /s/ David Weden

		 	Name: David Weden
		 	Title:   Authorized Signatory
	  
 INVESTOR:

 

	 Portland Magenta PIA, LLC
  

	By:	 	 Partners HealthCare System Pooled Investment Accounts, LLC, its managing member

 

	By:	 	 /s/ David Weden

		 	Name: David Weden
		 	Title:   Authorized Signatory

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ David Scadden

	Name: David Scadden

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Jeffrey Albers

	Name: Jeffrey Albers

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Zoran Zdraveski

	Name: Zoran Zdraveski

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Manisha Pai

	Name: Manisha Pai

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ John Davis

	Name: John Davis

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Derrick Rossi

	 Name: Derrick Rossi

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

					
	 INVESTORS:
  

	    	 	 /s/ Jason Gardner

Name: Jason Gardner
  

		 	 J.P. GARDNER IRREVOCABLE TRUST
  

		 	By:	 	 /s/ Patcharin S. Gardner 

		 		 	 Name: Patcharin S. Gardner
Title: Trustee

 

		 	By:	 	 /s/ Peter M. Frasca

		 		 	 Name: Peter M. Frasca, Esq.
Title: Trustee

 

		 	 P.S. GARDNER IRREVOCABLE TRUST
  

		 	By:	 	 /s/ Jason P. Gardner 

		 		 	 Name: Jason P. Gardner
Title: Trustee

		 	By:	 	  
 /s/ Peter M. Frasca

		 		 	 Name: Peter M. Frasca, Esq.
Title: Trustee

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Bastiano Sanna

	Name: Bastiano Sanna

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Michael Cooke

	Name: Michael Cooke

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Christina Isacson

	Name: Christina Isacson

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Thomas Daniel

	Name: Thomas Daniel

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	 INVESTOR:
  

	 /s/ Michael Bonney

	Name: Michael Bonney

  
 [Signature Page to Second
Amended and Restated Investors’ Rights Agreement] 

 SCHEDULE A 

INVESTORS 
 Name and Address

 Third Rock Ventures IV, L.P. 
 29 Newbury
Street, 3rd Floor 
 Boston, MA 02116 
 Atlas Venture Fund
X, L.P. 
 400 Technology Square, 10th Floor 

Cambridge, MA 02139Attention: Ommer Chohan 
 E-mail: ommer@atlasventure.com, with a copy to bruce@atlasventure.com 
 GV 2016, L.P. 

Email: notice@gv.com 
 Attn: Daphne M. Chang 

1600 Amphitheatre Parkway 
 Mountain View, CA 94043 

Be The Match BioTherapies, LLC 
 500 N. 5th Street 

Minneapolis, Minnesota 55401-1206 
 Attn: Amy Ronneberg 

Novartis Institutes for Biomedical Research, Inc. 
 250
Massachusetts Avenue 
 Cambridge, MA 02139 
 Access
Industries Holdings LLC 
 c/o Access Industries Management, LLC 

730 Fifth Avenue, 20th Floor 
 New York, New York 10019 

Partners Innovation Fund LLC 
 215 First Street 

Cambridge, MA 02142 
 Partners Innovation Fund II, LP 

215 First Street 
 Cambridge, MA 02142 

Casdin Partners Master Fund, LP 
 1350 Avenue of the
Americas, 24th Floor 
 New York, NY 10019 

 Casdin Venture Opportunities Fund, LP 

1350 Avenue of the Americas, 24th Floor 

New York, NY 10019 
 Robert W. Postma 

Mutual Fund Series Trust, on Behalf of Eventide Healthcare and Life Sciences Fund 

Mutual Fund Series Trust, on Behalf of Eventide Gilead Fund 

EcoR1 Capital Fund, LP 
 EcoR1 Capital Fund Qualified,
LP 
 Harvard Management Private Equity Corporation 

600 Atlantic Avenue 
 Boston, MA 02210 

Attn: Elise McDonald and Emily Carroll 
 Email:
mcdonald@hmc.harvard.edu; carrolle@hmc.harvard.edu 
 Fifth Avenue Private Equity 14 LLC 

Bessemer Trust Company, N.A. 
 630 Fifth Avenue 

New York, NY 10111 
 Email: PrivateEquity@bessemer.com 

SCubed Capital, LLC 
 2061 Avy Avenue 

Menlo Park, CA 94025 
 Attention: Mark Stevens, mark@scubedcap.com

 Margo Doyle, margo@scubedcap.com 
 Please also copy
finance@scubedcap.com for any communications. 
 PH Investments, LLC 

Pilot House, Lewis Wharf 
 Boston, MA 02110 

Attention: Ben Gomez; John Vander Vort; April Robinson 
 Email:
Ben.Gomez@pilothouse.com 
 John.VanderVort@pilothouse.com 

April.Robinson@pilothouse.com 
 Sobrato Family Holdings, LLC

 10600 N. De Anza Blvd., Suite 200 
 Cupertino, CA 95014

 Phone: 408-446-0700 

Attn: Matt Sonsini and Albert Chiang 
 Email:
investments@sobrato.com 

 Portland Magenta EP, LLC 

Partners HealthCare Investment Office 
 101 Merrimac St., 8th
Floor 
 Boston, MA 02114 
 Attn: Kate Kamm, Portfolio Manager

 Phone: 857-277-7264 

Email: kkam@partnersinvest.org; copy to pephs@partnersinvest.org 

Portland Magenta PIA, LLC 
 Partners HealthCare Investment
Office 
 101 Merrimac St., 8th Floor 
 Boston, MA 02114 

Attn: Kate Kamm, Portfolio Manager 
 Phone: 857-277-7264 
 Email: kkam@partnersinvest.org; copy to
pephs@partnersinvest.org 
 David Scadden 
 Derrick Rossi 

Jason Gardner 
 J.P. Gardner Irrevocable Trust 

P.S. Gardner Irrevocable Trust 
 Bastiano Sanna 

Michael Cooke 
 Christina Isacson 

Thomas Daniel 
 Michael Bonney 

Jeffrey Albers 
 Manisha Pai 

Zoran Zdraveski 
 John Davis 

  
 59

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]